Explanation
This regulatory network was inferred from the input dataset. The miRNAs and mRNAs are
presented as round and rectangle nodes respectively. The numerical value popped up upon mouse over the gene node is the log2 transformed fold-change of the gene expression between the two groups. All of the nodes are clickable, and the detailed information of the miRNAs/mRNAs and related cancer pathway will be displayed in another window. The edges between nodes are supported by both interactions (predicted or experimentally verified) and correlations learnt from cancer dataset. The numerical value popped up upon mouse over the edge is the correlation beat value (effect size) between the two nodes. The experimental evidences of the edges reported in previous cancer studies are highlighted by red/orange color. All of these information can be accessed by the "mouse-over" action. This network shows a full map of the miRNA-mRNA regulation of the input gene list(s), and the hub miRNAs (with the high network degree/betweenness centrality) would be the potential cancer drivers or tumor suppressors. The full result table can be accessed in the "Regulations" tab.
"miRNACancerMAP" is also a network visualization tool for users to draw their regulatory network by personal customization. Users can set the complexity of the network by limiting the number of nodes or edges. And the color of the nodes can be defined by different categories of the mRNAs and miRNAs, such as Gene-Ontology, pathway, and expression status. Users can also select to use network degree or network betweenness centrality to define the node size. And edges can be black or colored by the correlation. Purple edge means negative correlation (mostly found between miRNA and mRNA), and blue edge means positive correlation (found in PPI or miRNA-miRNA sponge effect). We can also add the protein-protein interactions (PPI) into the network. This result will show the cluster of genes regulated by some specific miRNAs. Additionally, miRNA-miRNA edges can be added by the "miRNA sponge" button, presenting some clusters of miRNAs that have the interactions via sponge effect.
miRNA-gene regulations
| Num | microRNA | Gene | miRNA log2FC | miRNA pvalue | Gene log2FC | Gene pvalue | Interaction | Correlation beta | Correlation P-value | PMID | Reported in cancer studies |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | hsa-miR-15b-3p | ABL1 | 3.58 | 0 | -1.72 | 0 | MirTarget | -0.13 | 0.00015 | NA | |
| 2 | hsa-miR-15b-5p | ABL1 | 3.32 | 0 | -1.72 | 0 | mirMAP | -0.11 | 0.00854 | NA | |
| 3 | hsa-miR-16-5p | ABL1 | 2.94 | 0 | -1.72 | 0 | mirMAP | -0.11 | 0.00756 | NA | |
| 4 | hsa-miR-30e-5p | ABL1 | 0.78 | 0.03467 | -1.72 | 0 | MirTarget; miRNATAP | -0.18 | 0.00086 | NA | |
| 5 | hsa-miR-203a-3p | ATM | 6.35 | 0 | -0.66 | 0.11688 | MirTarget | -0.11 | 0 | 24145123; 27542403 | miR 203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase; In silico analysis identified ataxia telangiectasia mutated ATM a primary mediator of the DNA damage response as a potential target of miR-203; Using TCGA database we identified a significant reverse correlation of miR-203 and ATM expression in CRC tissues; We validated ATM as a bona fide target of miR-203 in CRC cells; Mutation of the putative miR-203 binding site in the 3' untranslated region 3'UTR of the ATM mRNA abolished the inhibitory effect of miR-203 on ATM;MiR 203 inhibits tumor invasion and metastasis in gastric cancer by ATM; Our results showed that miR-203 was significantly downregulated in gastric cancer tissues and cells while ataxia telangiectasia mutated kinase ATM was upregulated in gastric cancer tissues and cells and was directly regulated by miR-203; ATM knockdown phenocopied the effect of miR-203 overexpression |
| 6 | hsa-miR-27a-5p | ATM | 1.45 | 0.03942 | -0.66 | 0.11688 | MirTarget | -0.12 | 0.00046 | NA | |
| 7 | hsa-miR-30e-3p | ATM | -0.04 | 0.93258 | -0.66 | 0.11688 | mirMAP | -0.16 | 0.0051 | NA | |
| 8 | hsa-miR-339-5p | ATM | 1.23 | 0.03075 | -0.66 | 0.11688 | miRanda | -0.16 | 0.00017 | NA | |
| 9 | hsa-miR-590-5p | ATM | 1.51 | 0.00239 | -0.66 | 0.11688 | mirMAP | -0.13 | 0.00485 | NA | |
| 10 | hsa-miR-29a-5p | ATR | 0.07 | 0.88413 | 1.12 | 0.00118 | mirMAP | -0.13 | 0.00077 | NA | |
| 11 | hsa-miR-30a-5p | ATR | -0.77 | 0.32049 | 1.12 | 0.00118 | mirMAP | -0.11 | 1.0E-5 | NA | |
| 12 | hsa-miR-10b-3p | BUB1 | -2.52 | 0 | 5.49 | 0 | MirTarget | -0.16 | 0.00147 | NA | |
| 13 | hsa-miR-199a-5p | BUB1 | -1.25 | 0.07478 | 5.49 | 0 | miRanda | -0.12 | 0.00146 | NA | |
| 14 | hsa-miR-199b-5p | BUB1 | -0.54 | 0.47689 | 5.49 | 0 | miRanda | -0.12 | 0.00047 | NA | |
| 15 | hsa-miR-30e-5p | CCNA1 | 0.78 | 0.03467 | -3.47 | 0.08554 | MirTarget | -0.99 | 0.00158 | NA | |
| 16 | hsa-let-7a-5p | CCND1 | 0.15 | 0.64531 | 0.15 | 0.87753 | TargetScan; miRNATAP | -0.54 | 0.00245 | NA | |
| 17 | hsa-miR-106a-5p | CCND1 | 3.99 | 0 | 0.15 | 0.87753 | MirTarget; miRNATAP | -0.43 | 0 | NA | |
| 18 | hsa-miR-15a-5p | CCND1 | 2.05 | 0 | 0.15 | 0.87753 | miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP | -0.35 | 0.00776 | 22922827 | CCND1 has been found to be a target of miR-15a and miR-16-1 through analysis of complementary sequences between microRNAs and CCND1 mRNA; Moreover the transcription of CCND1 is suppressed by miR-15a and miR-16-1 via direct binding to the CCND1 3'-untranslated region 3'-UTR |
| 19 | hsa-miR-15b-5p | CCND1 | 3.32 | 0 | 0.15 | 0.87753 | miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP | -0.42 | 0.00029 | NA | |
| 20 | hsa-miR-20b-5p | CCND1 | 4.57 | 5.0E-5 | 0.15 | 0.87753 | MirTarget; miRNATAP | -0.31 | 0 | NA | |
| 21 | hsa-miR-34a-5p | CCND1 | 0.83 | 0.04775 | 0.15 | 0.87753 | miRNAWalker2 validate; miRTarBase; miRNATAP | -0.42 | 0.00174 | 25792709; 21399894 | This inhibition of proliferation was associated with a decrease in cyclin D1 levels orchestrated principally by HNF-4α a target of miR-34a considered to act as a tumour suppressor in the liver;Quantitative PCR and western analysis confirmed decreased expression of two genes BCL-2 and CCND1 in docetaxel-resistant cells which are both targeted by miR-34a |
| 22 | hsa-miR-497-5p | CCND1 | -1.44 | 0.02251 | 0.15 | 0.87753 | MirTarget; miRNATAP | -0.25 | 0.00498 | 21350001 | Raf-1 and Ccnd1 were identified as novel direct targets of miR-195 and miR-497 miR-195/497 expression levels in clinical specimens were found to be correlated inversely with malignancy of breast cancer |
| 23 | hsa-miR-106a-5p | CCND2 | 3.99 | 0 | -2.81 | 0.0014 | miRNATAP | -0.44 | 0 | NA | |
| 24 | hsa-miR-106b-5p | CCND2 | 2.81 | 0 | -2.81 | 0.0014 | miRNAWalker2 validate; miRTarBase; miRNATAP | -0.31 | 0.00374 | NA | |
| 25 | hsa-miR-10a-3p | CCND2 | 0.97 | 0.31667 | -2.81 | 0.0014 | mirMAP | -0.2 | 0.00011 | NA | |
| 26 | hsa-miR-130b-5p | CCND2 | 3.74 | 0 | -2.81 | 0.0014 | mirMAP | -0.46 | 0 | NA | |
| 27 | hsa-miR-141-3p | CCND2 | 7.3 | 0 | -2.81 | 0.0014 | MirTarget; TargetScan | -0.24 | 0.00021 | NA | |
| 28 | hsa-miR-15b-5p | CCND2 | 3.32 | 0 | -2.81 | 0.0014 | miRNATAP | -0.53 | 0 | NA | |
| 29 | hsa-miR-16-2-3p | CCND2 | 3.8 | 0 | -2.81 | 0.0014 | mirMAP | -0.29 | 0.00207 | NA | |
| 30 | hsa-miR-182-5p | CCND2 | 5.87 | 0 | -2.81 | 0.0014 | miRNAWalker2 validate; miRTarBase; miRNATAP | -0.28 | 2.0E-5 | NA | |
| 31 | hsa-miR-183-5p | CCND2 | 6.62 | 0 | -2.81 | 0.0014 | miRNATAP | -0.29 | 0 | NA | |
| 32 | hsa-miR-191-5p | CCND2 | 1.59 | 0.00074 | -2.81 | 0.0014 | MirTarget | -0.32 | 0.00314 | NA | |
| 33 | hsa-miR-200a-3p | CCND2 | 6.34 | 0 | -2.81 | 0.0014 | MirTarget | -0.41 | 0 | NA | |
| 34 | hsa-miR-20b-5p | CCND2 | 4.57 | 5.0E-5 | -2.81 | 0.0014 | miRNATAP | -0.3 | 0 | NA | |
| 35 | hsa-miR-224-3p | CCND2 | 2.85 | 0.00018 | -2.81 | 0.0014 | mirMAP | -0.22 | 0.00101 | NA | |
| 36 | hsa-miR-28-5p | CCND2 | -0.82 | 0.02212 | -2.81 | 0.0014 | miRanda | -0.43 | 0.00273 | NA | |
| 37 | hsa-miR-3065-3p | CCND2 | 1.89 | 0.03082 | -2.81 | 0.0014 | MirTarget; miRNATAP | -0.21 | 0.00027 | NA | |
| 38 | hsa-miR-3065-5p | CCND2 | 2.14 | 0.06094 | -2.81 | 0.0014 | mirMAP | -0.2 | 0.00026 | NA | |
| 39 | hsa-miR-30d-3p | CCND2 | -0.07 | 0.85742 | -2.81 | 0.0014 | mirMAP | -0.55 | 1.0E-5 | NA | |
| 40 | hsa-miR-324-3p | CCND2 | 1.51 | 0.00384 | -2.81 | 0.0014 | miRNAWalker2 validate | -0.44 | 0 | NA | |
| 41 | hsa-miR-33a-3p | CCND2 | 2.06 | 0.00156 | -2.81 | 0.0014 | MirTarget | -0.27 | 0.00041 | NA | |
| 42 | hsa-miR-378a-3p | CCND2 | 1.47 | 0.04667 | -2.81 | 0.0014 | miRNAWalker2 validate | -0.19 | 0.00601 | NA | |
| 43 | hsa-miR-429 | CCND2 | 6.4 | 0 | -2.81 | 0.0014 | miRNATAP | -0.46 | 0 | NA | |
| 44 | hsa-miR-497-5p | CCND2 | -1.44 | 0.02251 | -2.81 | 0.0014 | MirTarget; miRNATAP | -0.27 | 0.00058 | NA | |
| 45 | hsa-miR-550a-5p | CCND2 | 1.22 | 0.06138 | -2.81 | 0.0014 | MirTarget | -0.22 | 0.00363 | NA | |
| 46 | hsa-miR-660-5p | CCND2 | -0.07 | 0.88525 | -2.81 | 0.0014 | mirMAP | -0.29 | 0.00793 | NA | |
| 47 | hsa-miR-9-3p | CCND2 | 1.69 | 0.12517 | -2.81 | 0.0014 | MirTarget; mirMAP; miRNATAP | -0.14 | 0.00185 | NA | |
| 48 | hsa-miR-93-5p | CCND2 | 2.66 | 0 | -2.81 | 0.0014 | miRNATAP | -0.48 | 0 | NA | |
| 49 | hsa-miR-96-5p | CCND2 | 5.63 | 0 | -2.81 | 0.0014 | TargetScan; miRNATAP | -0.24 | 0.0003 | NA | |
| 50 | hsa-miR-27b-3p | CCND3 | -0.09 | 0.85847 | -0.54 | 0.12437 | miRNAWalker2 validate | -0.14 | 0.00019 | NA | |
| 51 | hsa-miR-429 | CCND3 | 6.4 | 0 | -0.54 | 0.12437 | miRNATAP | -0.11 | 1.0E-5 | NA | |
| 52 | hsa-miR-96-5p | CCND3 | 5.63 | 0 | -0.54 | 0.12437 | TargetScan | -0.12 | 1.0E-5 | NA | |
| 53 | hsa-miR-125b-5p | CCNE1 | -2.01 | 0.00516 | 3.91 | 0 | miRNAWalker2 validate | -0.13 | 0.00065 | NA | |
| 54 | hsa-miR-195-5p | CCNE1 | -1.59 | 0.01691 | 3.91 | 0 | miRNAWalker2 validate; MirTarget; miRNATAP | -0.12 | 0.0047 | 24402230 | Furthermore through qPCR and western blot assays we showed that overexpression of miR-195-5p reduced CCNE1 mRNA and protein levels respectively |
| 55 | hsa-miR-26a-5p | CCNE1 | -0.35 | 0.36204 | 3.91 | 0 | miRNAWalker2 validate; miRTarBase; miRNATAP | -0.18 | 0.00988 | 22094936 | Cell cycle regulation and CCNE1 and CDC2 were the only significant overlapping pathway and genes differentially expressed between tumors with high and low levels of miR-26a and EZH2 respectively; Low mRNA levels of EZH2 CCNE1 and CDC2 and high levels of miR-26a are associated with favorable outcome on tamoxifen |
| 56 | hsa-miR-497-5p | CCNE1 | -1.44 | 0.02251 | 3.91 | 0 | MirTarget; miRNATAP | -0.13 | 0.00315 | 24909281; 24112607; 25909221 | miR 497 suppresses proliferation of human cervical carcinoma HeLa cells by targeting cyclin E1; Furthermore the target effect of miR-497 on the CCNE1 was identified by dual-luciferase reporter assay system qRT-PCR and Western blotting; Over-expressed miR-497 in HeLa cells could suppress cell proliferation by targeting CCNE1;Western blot assays confirmed that overexpression of miR-497 reduced cyclin E1 protein levels; Inhibited cellular growth suppressed cellular migration and invasion and G1 cell cycle arrest were observed upon overexpression of miR-497 in cells possibly by targeting cyclin E1;The effect of simultaneous overexpression of miR-497 and miR-34a on the inhibition of cell proliferation colony formation and tumor growth and the downregulation of cyclin E1 was stronger than the effect of each miRNA alone; The synergistic actions of miR-497 and miR-34a partly correlated with cyclin E1 levels; These results indicate cyclin E1 is downregulated by both miR-497 and miR-34a which synergistically retard the growth of human lung cancer cells |
| 57 | hsa-miR-28-3p | CCNE2 | -0.99 | 0.01882 | 4.78 | 0 | PITA; miRNATAP | -0.21 | 0.00739 | NA | |
| 58 | hsa-miR-30a-5p | CCNE2 | -0.77 | 0.32049 | 4.78 | 0 | miRNATAP | -0.23 | 0 | NA | |
| 59 | hsa-let-7a-3p | CDC14A | 0.83 | 0.04681 | -0.95 | 0.1553 | mirMAP | -0.31 | 0.00067 | NA | |
| 60 | hsa-let-7f-1-3p | CDC14A | 1.62 | 0.00069 | -0.95 | 0.1553 | mirMAP | -0.42 | 0 | NA | |
| 61 | hsa-miR-142-3p | CDC14A | 4.35 | 0 | -0.95 | 0.1553 | miRanda | -0.19 | 0.00031 | NA | |
| 62 | hsa-miR-146b-5p | CDC14A | 1.88 | 0.00074 | -0.95 | 0.1553 | miRanda | -0.19 | 0.0048 | NA | |
| 63 | hsa-miR-330-3p | CDC14A | 2.49 | 0.00013 | -0.95 | 0.1553 | mirMAP | -0.22 | 0.00016 | NA | |
| 64 | hsa-miR-342-3p | CDC14A | 1.31 | 0.02072 | -0.95 | 0.1553 | miRanda | -0.27 | 4.0E-5 | NA | |
| 65 | hsa-miR-590-3p | CDC14A | 2.35 | 0 | -0.95 | 0.1553 | PITA; miRanda; mirMAP; miRNATAP | -0.24 | 0.00112 | NA | |
| 66 | hsa-miR-944 | CDC14A | 7.21 | 0.00082 | -0.95 | 0.1553 | mirMAP | -0.15 | 0 | NA | |
| 67 | hsa-miR-193a-5p | CDC14B | 0.51 | 0.23928 | -0.58 | 0.39082 | miRNATAP | -0.31 | 0.00039 | NA | |
| 68 | hsa-miR-27b-3p | CDC14B | -0.09 | 0.85847 | -0.58 | 0.39082 | miRNATAP | -0.22 | 0.00309 | NA | |
| 69 | hsa-miR-944 | CDC14B | 7.21 | 0.00082 | -0.58 | 0.39082 | PITA; mirMAP; miRNATAP | -0.11 | 0 | NA | |
| 70 | hsa-let-7c-5p | CDC25A | -2.04 | 0.02284 | 4.21 | 0 | MirTarget | -0.12 | 4.0E-5 | 25909324 | MicroRNA let 7c Inhibits Cell Proliferation and Induces Cell Cycle Arrest by Targeting CDC25A in Human Hepatocellular Carcinoma; The aim of the present study was to determine whether the cell cycle regulator CDC25A is involved in the antitumor effect of let-7c in HCC; The luciferase reporter assay showed that CDC25A was a direct target of let-7c and that let-7c inhibited the expression of CDC25A protein by directly targeting its 3' UTR; In conclusion this study indicates that let-7c suppresses HCC progression possibly by directly targeting the cell cycle regulator CDC25A and indirectly affecting its downstream target molecules |
| 71 | hsa-miR-195-5p | CDC25A | -1.59 | 0.01691 | 4.21 | 0 | MirTarget; miRNATAP | -0.13 | 0.00108 | NA | |
| 72 | hsa-miR-199a-5p | CDC6 | -1.25 | 0.07478 | 5.87 | 0 | miRanda | -0.15 | 8.0E-5 | NA | |
| 73 | hsa-miR-199b-5p | CDC6 | -0.54 | 0.47689 | 5.87 | 0 | miRanda | -0.12 | 0.0007 | NA | |
| 74 | hsa-miR-140-5p | CDK2 | -0.63 | 0.12667 | 1.42 | 2.0E-5 | miRanda | -0.12 | 0.00814 | NA | |
| 75 | hsa-let-7a-5p | CDK6 | 0.15 | 0.64531 | 0.5 | 0.55124 | miRNAWalker2 validate; miRTarBase; TargetScan | -0.65 | 2.0E-5 | NA | |
| 76 | hsa-let-7b-5p | CDK6 | -0.19 | 0.65188 | 0.5 | 0.55124 | miRNAWalker2 validate; miRTarBase | -0.47 | 5.0E-5 | NA | |
| 77 | hsa-miR-101-3p | CDK6 | -1.12 | 0.02009 | 0.5 | 0.55124 | mirMAP | -0.42 | 2.0E-5 | NA | |
| 78 | hsa-miR-106a-5p | CDK6 | 3.99 | 0 | 0.5 | 0.55124 | mirMAP | -0.39 | 0 | NA | |
| 79 | hsa-miR-141-3p | CDK6 | 7.3 | 0 | 0.5 | 0.55124 | TargetScan; miRNATAP | -0.2 | 0.0009 | NA | |
| 80 | hsa-miR-148b-3p | CDK6 | 1.76 | 0 | 0.5 | 0.55124 | mirMAP | -0.47 | 0.00118 | NA | |
| 81 | hsa-miR-200a-3p | CDK6 | 6.34 | 0 | 0.5 | 0.55124 | miRNATAP | -0.35 | 0 | 24009066 | microRNA 200a is an independent prognostic factor of hepatocellular carcinoma and induces cell cycle arrest by targeting CDK6 |
| 82 | hsa-miR-200b-3p | CDK6 | 5.56 | 0 | 0.5 | 0.55124 | mirMAP | -0.39 | 0 | NA | |
| 83 | hsa-miR-20b-5p | CDK6 | 4.57 | 5.0E-5 | 0.5 | 0.55124 | mirMAP | -0.28 | 0 | 26166554 | The transfection of miR-20b into EJ cells induced G1 phase cell cycle arrest via the decreased expression of cyclin D1 CDK2 and CDK6 without affecting another G1 phase cell cycle regulator cyclin E |
| 84 | hsa-miR-30a-5p | CDK6 | -0.77 | 0.32049 | 0.5 | 0.55124 | mirMAP | -0.17 | 0.00517 | NA | |
| 85 | hsa-miR-30d-5p | CDK6 | 0.3 | 0.38019 | 0.5 | 0.55124 | mirMAP | -0.5 | 0.00043 | NA | |
| 86 | hsa-miR-30e-5p | CDK6 | 0.78 | 0.03467 | 0.5 | 0.55124 | mirMAP | -0.54 | 4.0E-5 | NA | |
| 87 | hsa-miR-34a-5p | CDK6 | 0.83 | 0.04775 | 0.5 | 0.55124 | miRNAWalker2 validate; miRTarBase; miRNATAP | -0.36 | 0.00175 | 21702042; 26104764 | Molecular analyses identified Cdk6 and sirtuin SIRT-1 as being targeted by miR-34a in MI-TCC cells however inhibition of Cdk6 and SIRT-1 was not as effective as pre-miR-34a in mediating chemosensitization;The expression of microRNA 34a is inversely correlated with c MET and CDK6 and has a prognostic significance in lung adenocarcinoma patients; We found significant inverse correlations between miR-34a and c-MET R = -0.316 P = 0.028 and CDK6 expression R = -0.4582 P = 0.004 |
| 88 | hsa-miR-362-5p | CDK6 | -1.22 | 0.04527 | 0.5 | 0.55124 | mirMAP | -0.29 | 0.00026 | NA | |
| 89 | hsa-miR-429 | CDK6 | 6.4 | 0 | 0.5 | 0.55124 | mirMAP; miRNATAP | -0.25 | 4.0E-5 | NA | |
| 90 | hsa-miR-497-5p | CDK6 | -1.44 | 0.02251 | 0.5 | 0.55124 | miRNATAP | -0.31 | 3.0E-5 | NA | |
| 91 | hsa-miR-502-3p | CDK6 | -0.1 | 0.80889 | 0.5 | 0.55124 | PITA; miRNATAP | -0.42 | 0.00027 | NA | |
| 92 | hsa-miR-592 | CDK6 | 2.8 | 0.02935 | 0.5 | 0.55124 | mirMAP | -0.23 | 0 | NA | |
| 93 | hsa-miR-660-5p | CDK6 | -0.07 | 0.88525 | 0.5 | 0.55124 | mirMAP | -0.37 | 0.00036 | NA | |
| 94 | hsa-miR-542-3p | CDK7 | -0.38 | 0.438 | 0.58 | 0.07443 | miRanda | -0.12 | 0.00173 | NA | |
| 95 | hsa-let-7e-5p | CDKN1A | -0.11 | 0.81474 | 0.58 | 0.35758 | MirTarget | -0.27 | 0.00026 | NA | |
| 96 | hsa-let-7g-5p | CDKN1A | 0.86 | 0.00648 | 0.58 | 0.35758 | MirTarget | -0.32 | 0.00586 | NA | |
| 97 | hsa-miR-125a-5p | CDKN1A | -1.32 | 0.00714 | 0.58 | 0.35758 | miRNAWalker2 validate; miRTarBase | -0.35 | 0 | NA | |
| 98 | hsa-miR-28-5p | CDKN1A | -0.82 | 0.02212 | 0.58 | 0.35758 | miRNAWalker2 validate; miRTarBase; MirTarget; miRanda; miRNATAP | -0.55 | 0 | NA | |
| 99 | hsa-miR-30b-3p | CDKN1A | 0.17 | 0.76608 | 0.58 | 0.35758 | MirTarget | -0.16 | 0.00864 | NA | |
| 100 | hsa-miR-335-5p | CDKN1A | 0.17 | 0.8039 | 0.58 | 0.35758 | miRNAWalker2 validate | -0.25 | 0 | NA | |
| 101 | hsa-miR-345-5p | CDKN1A | 2.77 | 4.0E-5 | 0.58 | 0.35758 | miRNAWalker2 validate; miRTarBase; MirTarget | -0.23 | 1.0E-5 | NA | |
| 102 | hsa-miR-423-3p | CDKN1A | 1.71 | 2.0E-5 | 0.58 | 0.35758 | miRNAWalker2 validate; miRTarBase | -0.27 | 0.00253 | NA | |
| 103 | hsa-miR-505-5p | CDKN1A | -0.55 | 0.33141 | 0.58 | 0.35758 | miRNAWalker2 validate; MirTarget | -0.18 | 0.00519 | NA | |
| 104 | hsa-miR-616-5p | CDKN1A | 2.48 | 0.00318 | 0.58 | 0.35758 | mirMAP | -0.14 | 0.0061 | NA | |
| 105 | hsa-miR-96-5p | CDKN1A | 5.63 | 0 | 0.58 | 0.35758 | miRNAWalker2 validate; miRTarBase | -0.17 | 0.00034 | 26582573 | Upregulation of microRNA 96 and its oncogenic functions by targeting CDKN1A in bladder cancer; Bioinformatics prediction combined with luciferase reporter assay were used to verify whether the cyclin-dependent kinase inhibitor CDKN1A was a potential target gene of miR-96; According to the data of miRTarBase CDKN1A might be a candidate target gene of miR-96; In addition luciferase reporter and Western blot assays respectively demonstrated that miR-96 could bind to the putative seed region in CDKN1A mRNA 3'UTR and significantly reduce the expression level of CDKN1A protein; Moreover we found that the inhibition of miR-96 expression remarkably decreased cell proliferation and promoted cell apoptosis of BC cell lines which was consistent with the findings observed following the introduction of CDKN1A cDNA without 3'UTR restored miR-96; Upregulation of miR-96 may contribute to aggressive malignancy partly through suppressing CDKN1A protein expression in BC cells |
| 106 | hsa-miR-221-3p | CDKN1B | 0.94 | 0.17475 | -0.76 | 0.02874 | miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP | -0.2 | 0 | 23637992; 19953484; 23939688; 19126397; 20146005; 23967190; 17569667; 22992757; 17721077; 20461750 | miR-221 knockdown not only blocked cell cycle progression induced cell apoptosis and inhibited cell proliferation in-vitro but it also inhibited in-vivo tumor growth by targeting p27kip1;Based on bioinformatic analysis we found that the seed sequences of miR-221 and miR-222 coincide with each other and p27kip1 is a target for miRNA-221/222;A Slug/miR-221 network has been suggested linking miR-221 activity with the downregulation of a Slug repressor leading to Slug/miR-221 upregulation and p27Kip1 downregulation; Interference with this process can be achieved using antisense miRNA antagomiR molecules targeting miR-221 inducing the downregulation of Slug and the upregulation of p27Kip1;Moreover a series of functional assays demonstrated that mir-221 could directly inhibit cKit p27Kip1 and possibly other pivotal proteins in melanoma;Matched HCC and adjacent non-cancerous samples were assayed for the expression of miR-221 and three G1/S transition inhibitors: p27Kip1 p21WAF1/Cip1and TGF-β1 by in situ hybridization and immunohistochemistry respectively; Real time qRT-PCR was used to investigate miR-221 and p27Kip1 transcripts in different clinical stages; In result miR-221 and TGF-β1 are frequently up-regulated in HCC while p27Kip1 and p21WAF1/Cip1 proteins are frequently down-regulated; In conclusion miR-221 is important in tumorigenesis of HCC possibly by specifically down-regulating p27Kip1 a cell-cycle inhibitor;Additionally the PDGF-dependent increase in cell proliferation appears to be mediated by inhibition of a specific target of miR-221 and down-regulation of p27Kip1;miR 221 and miR 222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1; In all cell lines tested we show an inverse relationship between the expression of miR-221 and miR-222 and the cell cycle inhibitor p27Kip1; Consistently miR-221 and miR-222 knock-down through antisense LNA oligonucleotides increases p27Kip1 in PC3 cells and strongly reduces their clonogenicity in vitro;Peptide nucleic acids targeting miR 221 modulate p27Kip1 expression in breast cancer MDA MB 231 cells; Targeting miR-221 by PNA resulted in i lowering of the hybridization levels of miR-221 measured by RT-qPCR ii upregulation of p27Kip1 gene expression measured by RT-qPCR and western blot analysis;Antagonism of either microRNA 221 or 222 in glioblastoma cells also caused an increase in p27Kip1 levels and enhanced expression of the luciferase reporter gene fused to the p27Kip1 3'UTR;MiR 221 and MiR 222 alterations in sporadic ovarian carcinoma: Relationship to CDKN1B CDKNIC and overall survival; miR-221 and miR-222 negatively regulate expression of CDKN1B p27 and CDKN1C p57 two cell cycle regulators expressed in ovarian surface epithelium and down-regulated in ovarian carcinomas; In contrast CDKN1B expression was not associated with miR-221 or miR-222 expression |
| 107 | hsa-miR-222-3p | CDKN1B | 1.55 | 0.0223 | -0.76 | 0.02874 | miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP | -0.2 | 0 | 24895988; 19953484; 26912358; 24137356; 17569667; 27282281; 20461750 | MiR-222 plays an important role in the tumorigenesis of CC possibly by specifically down-regulating p27Kip1 and PTEN;Based on bioinformatic analysis we found that the seed sequences of miR-221 and miR-222 coincide with each other and p27kip1 is a target for miRNA-221/222;Besides microvesicle marker characterization we evidenced that miR-222 exosomal expression mostly reflected its abundance in the cells of origin correctly paralleled by repression of its target genes such as p27Kip1 and induction of the PI3K/AKT pathway thus confirming its functional implication in cancer;miR 222 is upregulated in epithelial ovarian cancer and promotes cell proliferation by downregulating P27kip1; miR-222 upregulation induced an enhancement of ovarian cancer cell proliferation potential possibly by downregulating its target P27Kip1; A bioinformatic analysis showed that the 3'-UTR of the P27Kip1 mRNA contained a highly-conserved putative miR-222 binding site; Luciferase reporter assays demonstrated that P27Kip1 was a direct target of miR-222; Consistently there was an inverse correlation between the P27Kip1 and miR-222 expression levels in the ovarian cancer cell lines and tissues;miR 221 and miR 222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1; In all cell lines tested we show an inverse relationship between the expression of miR-221 and miR-222 and the cell cycle inhibitor p27Kip1; Consistently miR-221 and miR-222 knock-down through antisense LNA oligonucleotides increases p27Kip1 in PC3 cells and strongly reduces their clonogenicity in vitro;miR 222 confers the resistance of breast cancer cells to Adriamycin through suppression of p27kip1 expression; Immunofluorescence showed that miR-222 altered the subcellular location of p27kip1 in nucleus; The results showed that downregulation of miR-222 in MCF-7/Adr increased sensitivity to Adr and Adr-induced apoptosis and arrested the cells in G1 phase accompanied by more expressions of p27kip1 especially in nucleus; Taken together the results found that miR-222 induced Adr-resistance at least in part via suppressing p27kip1 expression and altering its subcellular localization and miR-222 inhibitors could reverse Adr-resistance of breast cancer cells;MiR 221 and MiR 222 alterations in sporadic ovarian carcinoma: Relationship to CDKN1B CDKNIC and overall survival; miR-221 and miR-222 negatively regulate expression of CDKN1B p27 and CDKN1C p57 two cell cycle regulators expressed in ovarian surface epithelium and down-regulated in ovarian carcinomas; In contrast CDKN1B expression was not associated with miR-221 or miR-222 expression |
| 108 | hsa-miR-24-3p | CDKN1B | 1.56 | 0.00052 | -0.76 | 0.02874 | miRNAWalker2 validate; miRNATAP | -0.23 | 0 | 26847530; 26044523 | The biological significance of miR-24 expression in prostate cancer cells was assessed by a series of in vitro bioassays and the effect on proposed targets p27 CDKN1B and p16 CDK2NA was investigated;With the bioinformatic method we further identified that p27Kip1 is a direct target of miR-24-3p and its protein level was negatively regulated by miR-24-3p |
| 109 | hsa-miR-421 | CDKN1B | 1.98 | 0.00092 | -0.76 | 0.02874 | miRanda | -0.11 | 0.0006 | NA | |
| 110 | hsa-miR-455-5p | CDKN1B | -0.32 | 0.6163 | -0.76 | 0.02874 | miRanda; miRNATAP | -0.11 | 0.00022 | NA | |
| 111 | hsa-miR-221-3p | CDKN1C | 0.94 | 0.17475 | -2.67 | 0.00188 | miRNAWalker2 validate; miRTarBase; miRNATAP | -0.24 | 0.00065 | 20461750 | miR-221 and miR-222 negatively regulate expression of CDKN1B p27 and CDKN1C p57 two cell cycle regulators expressed in ovarian surface epithelium and down-regulated in ovarian carcinomas; Higher miR-222 and miR-221 expression were significantly associated with decreased CDKN1C expression P = 0.009 and 0.01 |
| 112 | hsa-miR-222-3p | CDKN1C | 1.55 | 0.0223 | -2.67 | 0.00188 | miRNAWalker2 validate; miRTarBase; miRNATAP | -0.24 | 0.00098 | 20461750 | miR-221 and miR-222 negatively regulate expression of CDKN1B p27 and CDKN1C p57 two cell cycle regulators expressed in ovarian surface epithelium and down-regulated in ovarian carcinomas; Higher miR-222 and miR-221 expression were significantly associated with decreased CDKN1C expression P = 0.009 and 0.01 |
| 113 | hsa-miR-10b-5p | CDKN2A | -3.08 | 0 | 7.38 | 0 | miRNAWalker2 validate; miRTarBase | -0.36 | 0.00054 | NA | |
| 114 | hsa-miR-125a-5p | CDKN2A | -1.32 | 0.00714 | 7.38 | 0 | miRanda | -0.39 | 0.00048 | NA | |
| 115 | hsa-miR-107 | CDKN2B | 1.49 | 0.00013 | 3.05 | 0.00021 | PITA | -0.45 | 0.00018 | NA | |
| 116 | hsa-miR-125a-3p | CDKN2B | -0.07 | 0.92074 | 3.05 | 0.00021 | miRanda | -0.28 | 1.0E-5 | NA | |
| 117 | hsa-miR-125a-5p | CDKN2B | -1.32 | 0.00714 | 3.05 | 0.00021 | miRanda | -0.61 | 0 | NA | |
| 118 | hsa-miR-126-5p | CDKN2B | -0.42 | 0.32997 | 3.05 | 0.00021 | mirMAP | -0.38 | 0.00047 | NA | |
| 119 | hsa-miR-217 | CDKN2B | -0.38 | 0.71741 | 3.05 | 0.00021 | miRanda | -0.15 | 0.00119 | NA | |
| 120 | hsa-miR-28-5p | CDKN2B | -0.82 | 0.02212 | 3.05 | 0.00021 | miRanda | -0.81 | 0 | NA | |
| 121 | hsa-miR-335-3p | CDKN2B | 1.2 | 0.09389 | 3.05 | 0.00021 | mirMAP | -0.23 | 0.00046 | NA | |
| 122 | hsa-miR-374b-5p | CDKN2B | -0.11 | 0.76489 | 3.05 | 0.00021 | miRNAWalker2 validate | -0.43 | 0.00059 | NA | |
| 123 | hsa-miR-375 | CDKN2B | 3.38 | 0.04499 | 3.05 | 0.00021 | miRNAWalker2 validate; miRNATAP | -0.14 | 0 | NA | |
| 124 | hsa-miR-450b-5p | CDKN2B | 0.45 | 0.41602 | 3.05 | 0.00021 | mirMAP | -0.27 | 0.00178 | NA | |
| 125 | hsa-miR-495-3p | CDKN2B | -1.28 | 0.09795 | 3.05 | 0.00021 | MirTarget | -0.18 | 0.00349 | NA | |
| 126 | hsa-miR-501-3p | CDKN2B | 1.72 | 0.00759 | 3.05 | 0.00021 | PITA | -0.38 | 0 | NA | |
| 127 | hsa-miR-501-5p | CDKN2B | 1.04 | 0.07772 | 3.05 | 0.00021 | mirMAP | -0.35 | 1.0E-5 | NA | |
| 128 | hsa-miR-502-3p | CDKN2B | -0.1 | 0.80889 | 3.05 | 0.00021 | PITA | -0.5 | 1.0E-5 | NA | |
| 129 | hsa-miR-582-5p | CDKN2B | 0.69 | 0.44776 | 3.05 | 0.00021 | miRNATAP | -0.14 | 0.00622 | NA | |
| 130 | hsa-miR-671-5p | CDKN2B | 1.49 | 0.00687 | 3.05 | 0.00021 | PITA | -0.35 | 3.0E-5 | NA | |
| 131 | hsa-miR-7-1-3p | CDKN2B | 1.43 | 0.00471 | 3.05 | 0.00021 | MirTarget | -0.36 | 0.00011 | NA | |
| 132 | hsa-miR-129-5p | CDKN2C | -2.67 | 0.00696 | 1.32 | 0.08126 | miRanda | -0.13 | 0.00311 | NA | |
| 133 | hsa-miR-192-5p | CDKN2D | 1.78 | 0.11349 | 0.74 | 0.16667 | miRNAWalker2 validate | -0.11 | 4.0E-5 | NA | |
| 134 | hsa-miR-21-3p | CREBBP | 3.5 | 0 | -0.4 | 0.18067 | MirTarget | -0.14 | 0 | NA | |
| 135 | hsa-miR-590-3p | CREBBP | 2.35 | 0 | -0.4 | 0.18067 | PITA; miRanda; mirMAP; miRNATAP | -0.1 | 0.00219 | NA | |
| 136 | hsa-let-7e-5p | E2F2 | -0.11 | 0.81474 | 6.82 | 0 | MirTarget | -0.35 | 2.0E-5 | NA | |
| 137 | hsa-miR-125a-5p | E2F2 | -1.32 | 0.00714 | 6.82 | 0 | MirTarget | -0.35 | 1.0E-5 | NA | |
| 138 | hsa-miR-30c-2-3p | E2F2 | -0.92 | 0.3002 | 6.82 | 0 | MirTarget | -0.21 | 0 | NA | |
| 139 | hsa-let-7b-5p | E2F3 | -0.19 | 0.65188 | 1.54 | 3.0E-5 | miRNAWalker2 validate | -0.15 | 0.00308 | NA | |
| 140 | hsa-miR-101-3p | E2F3 | -1.12 | 0.02009 | 1.54 | 3.0E-5 | miRNAWalker2 validate | -0.13 | 0.00286 | NA | |
| 141 | hsa-miR-125b-5p | E2F3 | -2.01 | 0.00516 | 1.54 | 3.0E-5 | miRNAWalker2 validate; miRTarBase; miRNATAP | -0.12 | 5.0E-5 | 22523546; 20549700 | Moreover we demonstrated that the E2F3 was a direct target of miR-125b in breast cancer cells;E2F3 which was critical for G1/S transition and was overexpressed in most of poor-differentiated bladder cancers was identified as a target of miR-125b by luciferase assay; Introduction of miR-125b could reduce the expression of E2F3 protein but not the E2F3 mRNA |
| 142 | hsa-miR-145-5p | E2F3 | -3.56 | 0 | 1.54 | 3.0E-5 | miRNATAP | -0.11 | 0.00021 | 25762621 | miR 145 mediates the antiproliferative and gene regulatory effects of vitamin D3 by directly targeting E2F3 in gastric cancer cells; Furthermore miR-145 expression was lower in tumors compared with matched normal samples and correlated with increased the E2F3 transcription factor protein staining |
| 143 | hsa-miR-221-3p | E2F3 | 0.94 | 0.17475 | 1.54 | 3.0E-5 | miRNAWalker2 validate | -0.1 | 0.00098 | NA | |
| 144 | hsa-miR-497-5p | E2F3 | -1.44 | 0.02251 | 1.54 | 3.0E-5 | miRNATAP | -0.12 | 0.00045 | NA | |
| 145 | hsa-let-7f-5p | E2F5 | 0.97 | 0.02403 | -0.64 | 0.41617 | MirTarget; miRNATAP | -0.35 | 0.00066 | NA | |
| 146 | hsa-let-7i-5p | E2F5 | 0.05 | 0.86971 | -0.64 | 0.41617 | MirTarget; miRNATAP | -0.49 | 0.00194 | NA | |
| 147 | hsa-miR-1-3p | E2F5 | -3.85 | 1.0E-5 | -0.64 | 0.41617 | MirTarget | -0.15 | 0.00306 | NA | |
| 148 | hsa-miR-142-3p | E2F5 | 4.35 | 0 | -0.64 | 0.41617 | miRanda | -0.17 | 0.00689 | NA | |
| 149 | hsa-miR-205-5p | E2F5 | 8.08 | 0 | -0.64 | 0.41617 | miRNAWalker2 validate; miRTarBase; miRNATAP | -0.18 | 0 | 21454583 | The expression levels of E2F1 and E2F5 were correlated inversely with that of miR-205 in melanoma cell lines; miR-205 significantly suppressed the luciferase activity of reporter plasmids containing the 3'-UTR sequences complementary to either E2F1 or E2F5; Overexpression of miR-205 in melanoma cells reduced E2F1 and E2F5 protein levels |
| 150 | hsa-miR-34c-5p | E2F5 | 2.65 | 0.01574 | -0.64 | 0.41617 | MirTarget; PITA; miRanda; miRNATAP | -0.16 | 9.0E-5 | NA |
| Num | GO | Overlap | Size | P Value | Adj. P Value |
|---|---|---|---|---|---|
| 1 | CELL CYCLE | 51 | 1316 | 1.017e-50 | 4.731e-47 |
| 2 | REGULATION OF CELL CYCLE | 46 | 949 | 1.589e-48 | 3.698e-45 |
| 3 | CELL CYCLE PROCESS | 47 | 1081 | 1.148e-47 | 1.781e-44 |
| 4 | MITOTIC CELL CYCLE | 40 | 766 | 4.475e-42 | 5.205e-39 |
| 5 | NEGATIVE REGULATION OF CELL CYCLE | 32 | 433 | 2.12e-37 | 1.973e-34 |
| 6 | CELL CYCLE CHECKPOINT | 24 | 194 | 4.856e-33 | 3.765e-30 |
| 7 | REGULATION OF MITOTIC CELL CYCLE | 28 | 468 | 9.18e-30 | 6.102e-27 |
| 8 | REGULATION OF CELL CYCLE PHASE TRANSITION | 25 | 321 | 2.797e-29 | 1.627e-26 |
| 9 | CELL CYCLE PHASE TRANSITION | 23 | 255 | 2.387e-28 | 1.234e-25 |
| 10 | NEGATIVE REGULATION OF MITOTIC CELL CYCLE | 21 | 199 | 2.636e-27 | 1.227e-24 |
| 11 | REGULATION OF PROTEIN MODIFICATION PROCESS | 39 | 1710 | 5.068e-27 | 2.144e-24 |
| 12 | CELL CYCLE G1 S PHASE TRANSITION | 18 | 111 | 6.356e-27 | 2.146e-24 |
| 13 | MITOTIC CELL CYCLE CHECKPOINT | 19 | 139 | 6.457e-27 | 2.146e-24 |
| 14 | G1 S TRANSITION OF MITOTIC CELL CYCLE | 18 | 111 | 6.356e-27 | 2.146e-24 |
| 15 | NEGATIVE REGULATION OF CELL CYCLE PROCESS | 21 | 214 | 1.275e-26 | 3.956e-24 |
| 16 | NEGATIVE REGULATION OF CELL CYCLE PHASE TRANSITION | 19 | 146 | 1.727e-26 | 4.728e-24 |
| 17 | DNA INTEGRITY CHECKPOINT | 19 | 146 | 1.727e-26 | 4.728e-24 |
| 18 | POSITIVE REGULATION OF CELL CYCLE | 23 | 332 | 1.141e-25 | 2.949e-23 |
| 19 | REGULATION OF TRANSFERASE ACTIVITY | 31 | 946 | 3.092e-25 | 7.572e-23 |
| 20 | REGULATION OF CELL CYCLE PROCESS | 26 | 558 | 1.063e-24 | 2.473e-22 |
| 21 | REGULATION OF CELL CYCLE G1 S PHASE TRANSITION | 18 | 147 | 1.345e-24 | 2.98e-22 |
| 22 | REGULATION OF PHOSPHORUS METABOLIC PROCESS | 36 | 1618 | 4.007e-24 | 8.475e-22 |
| 23 | REGULATION OF CYCLIN DEPENDENT PROTEIN KINASE ACTIVITY | 16 | 97 | 4.349e-24 | 8.798e-22 |
| 24 | NEGATIVE REGULATION OF CELL CYCLE G1 S PHASE TRANSITION | 16 | 98 | 5.186e-24 | 1.006e-21 |
| 25 | CELL CYCLE ARREST | 17 | 154 | 1.909e-22 | 3.554e-20 |
| 26 | CELL DIVISION | 23 | 460 | 2.028e-22 | 3.63e-20 |
| 27 | REGULATION OF KINASE ACTIVITY | 27 | 776 | 2.301e-22 | 3.965e-20 |
| 28 | REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 23 | 470 | 3.305e-22 | 5.492e-20 |
| 29 | G1 DNA DAMAGE CHECKPOINT | 14 | 73 | 3.908e-22 | 6.27e-20 |
| 30 | POSITIVE REGULATION OF CELL CYCLE PROCESS | 19 | 247 | 5.138e-22 | 7.968e-20 |
| 31 | NEGATIVE REGULATION OF PROTEIN METABOLIC PROCESS | 29 | 1087 | 5.948e-21 | 8.927e-19 |
| 32 | SIGNAL TRANSDUCTION IN RESPONSE TO DNA DAMAGE | 14 | 96 | 2.404e-20 | 3.496e-18 |
| 33 | MITOTIC DNA INTEGRITY CHECKPOINT | 14 | 100 | 4.4e-20 | 6.205e-18 |
| 34 | REGULATION OF CELL CYCLE ARREST | 14 | 108 | 1.367e-19 | 1.871e-17 |
| 35 | NEGATIVE REGULATION OF PROTEIN MODIFICATION PROCESS | 23 | 616 | 1.445e-19 | 1.921e-17 |
| 36 | POSITIVE REGULATION OF CELL CYCLE ARREST | 13 | 85 | 3.152e-19 | 4.073e-17 |
| 37 | CELLULAR RESPONSE TO DNA DAMAGE STIMULUS | 23 | 720 | 4.567e-18 | 5.743e-16 |
| 38 | POSITIVE REGULATION OF CELL DEATH | 21 | 605 | 3.478e-17 | 4.225e-15 |
| 39 | REGULATION OF CELL PROLIFERATION | 29 | 1496 | 3.542e-17 | 4.225e-15 |
| 40 | NEGATIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS | 20 | 541 | 6.924e-17 | 7.858e-15 |
| 41 | NEGATIVE REGULATION OF PHOSPHATE METABOLIC PROCESS | 20 | 541 | 6.924e-17 | 7.858e-15 |
| 42 | SIGNAL TRANSDUCTION BY P53 CLASS MEDIATOR | 13 | 127 | 7.385e-17 | 8.182e-15 |
| 43 | NEGATIVE REGULATION OF TRANSFERASE ACTIVITY | 17 | 351 | 2.573e-16 | 2.749e-14 |
| 44 | REGULATION OF CELL DEATH | 28 | 1472 | 2.6e-16 | 2.749e-14 |
| 45 | NEGATIVE REGULATION OF PHOSPHORYLATION | 18 | 422 | 2.739e-16 | 2.832e-14 |
| 46 | POSITIVE REGULATION OF PROTEIN METABOLIC PROCESS | 28 | 1492 | 3.679e-16 | 3.721e-14 |
| 47 | NEGATIVE REGULATION OF KINASE ACTIVITY | 15 | 250 | 7.886e-16 | 7.807e-14 |
| 48 | REGULATION OF ORGANELLE ORGANIZATION | 25 | 1178 | 1.586e-15 | 1.537e-13 |
| 49 | NEGATIVE REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 12 | 126 | 3.072e-15 | 2.917e-13 |
| 50 | POSITIVE REGULATION OF PROTEIN MODIFICATION PROCESS | 24 | 1135 | 7.726e-15 | 7.19e-13 |
| 51 | CELLULAR RESPONSE TO STRESS | 27 | 1565 | 1.242e-14 | 1.133e-12 |
| 52 | NEGATIVE REGULATION OF CELL PROLIFERATION | 19 | 643 | 2.801e-14 | 2.506e-12 |
| 53 | CELL DEATH | 22 | 1001 | 6.665e-14 | 5.851e-12 |
| 54 | POSITIVE REGULATION OF CELLULAR PROTEIN LOCALIZATION | 15 | 360 | 1.681e-13 | 1.449e-11 |
| 55 | MITOTIC NUCLEAR DIVISION | 15 | 361 | 1.75e-13 | 1.481e-11 |
| 56 | NEGATIVE REGULATION OF CATALYTIC ACTIVITY | 20 | 829 | 2.237e-13 | 1.859e-11 |
| 57 | POSITIVE REGULATION OF BIOSYNTHETIC PROCESS | 27 | 1805 | 3.933e-13 | 3.211e-11 |
| 58 | REGULATION OF CELLULAR PROTEIN LOCALIZATION | 17 | 552 | 4.277e-13 | 3.431e-11 |
| 59 | RESPONSE TO ABIOTIC STIMULUS | 21 | 1024 | 1.104e-12 | 8.709e-11 |
| 60 | ORGANELLE FISSION | 16 | 496 | 1.17e-12 | 9.074e-11 |
| 61 | POSITIVE REGULATION OF GENE EXPRESSION | 26 | 1733 | 1.229e-12 | 9.371e-11 |
| 62 | REGULATION OF CELL DIVISION | 13 | 272 | 1.501e-12 | 1.126e-10 |
| 63 | POSITIVE REGULATION OF RESPONSE TO STIMULUS | 27 | 1929 | 1.917e-12 | 1.416e-10 |
| 64 | NEGATIVE REGULATION OF MOLECULAR FUNCTION | 21 | 1079 | 2.999e-12 | 2.18e-10 |
| 65 | RESPONSE TO UV | 10 | 126 | 4.712e-12 | 3.373e-10 |
| 66 | POSITIVE REGULATION OF CELL COMMUNICATION | 24 | 1532 | 5.2e-12 | 3.666e-10 |
| 67 | DNA METABOLIC PROCESS | 18 | 758 | 6.059e-12 | 4.208e-10 |
| 68 | POSITIVE REGULATION OF ORGANELLE ORGANIZATION | 16 | 573 | 1.03e-11 | 7.05e-10 |
| 69 | CELLULAR RESPONSE TO RADIATION | 10 | 137 | 1.093e-11 | 7.371e-10 |
| 70 | CELL CYCLE G2 M PHASE TRANSITION | 10 | 138 | 1.176e-11 | 7.815e-10 |
| 71 | POSITIVE REGULATION OF PHOSPHATE METABOLIC PROCESS | 20 | 1036 | 1.327e-11 | 8.543e-10 |
| 72 | POSITIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS | 20 | 1036 | 1.327e-11 | 8.543e-10 |
| 73 | POSITIVE REGULATION OF MITOCHONDRIAL OUTER MEMBRANE PERMEABILIZATION INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 7 | 36 | 1.34e-11 | 8.543e-10 |
| 74 | REGULATION OF CELLULAR RESPONSE TO STRESS | 17 | 691 | 1.522e-11 | 9.57e-10 |
| 75 | POSITIVE REGULATION OF CELL PROLIFERATION | 18 | 814 | 1.97e-11 | 1.222e-09 |
| 76 | CELLULAR RESPONSE TO UV | 8 | 66 | 2.326e-11 | 1.424e-09 |
| 77 | REGULATION OF PROTEOLYSIS | 17 | 711 | 2.382e-11 | 1.439e-09 |
| 78 | REGULATION OF MITOCHONDRIAL OUTER MEMBRANE PERMEABILIZATION INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 7 | 43 | 5.089e-11 | 3.036e-09 |
| 79 | POSITIVE REGULATION OF INTRACELLULAR TRANSPORT | 13 | 370 | 7.101e-11 | 4.183e-09 |
| 80 | CHROMOSOME ORGANIZATION | 19 | 1009 | 7.566e-11 | 4.401e-09 |
| 81 | REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 24 | 1784 | 1.271e-10 | 7.303e-09 |
| 82 | REGULATION OF PROTEIN CATABOLIC PROCESS | 13 | 393 | 1.495e-10 | 8.485e-09 |
| 83 | REGULATION OF PROTEIN LOCALIZATION | 18 | 950 | 2.45e-10 | 1.373e-08 |
| 84 | REGULATION OF PROTEIN INSERTION INTO MITOCHONDRIAL MEMBRANE INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 6 | 29 | 2.813e-10 | 1.522e-08 |
| 85 | POSITIVE REGULATION OF PROTEIN INSERTION INTO MITOCHONDRIAL MEMBRANE INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 6 | 29 | 2.813e-10 | 1.522e-08 |
| 86 | RESPONSE TO RADIATION | 13 | 413 | 2.752e-10 | 1.522e-08 |
| 87 | CELLULAR RESPONSE TO LIGHT STIMULUS | 8 | 91 | 3.245e-10 | 1.716e-08 |
| 88 | PEPTIDYL AMINO ACID MODIFICATION | 17 | 841 | 3.225e-10 | 1.716e-08 |
| 89 | POSITIVE REGULATION OF TRANSFERASE ACTIVITY | 15 | 616 | 3.42e-10 | 1.77e-08 |
| 90 | POSITIVE REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION | 14 | 514 | 3.423e-10 | 1.77e-08 |
| 91 | REGULATION OF INTRACELLULAR TRANSPORT | 15 | 621 | 3.823e-10 | 1.952e-08 |
| 92 | CELLULAR RESPONSE TO ABIOTIC STIMULUS | 11 | 263 | 3.859e-10 | 1.952e-08 |
| 93 | POSITIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 18 | 1004 | 5.96e-10 | 2.982e-08 |
| 94 | REGULATION OF CHROMOSOME ORGANIZATION | 11 | 278 | 6.94e-10 | 3.435e-08 |
| 95 | POSITIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION | 19 | 1152 | 7.11e-10 | 3.482e-08 |
| 96 | RESPONSE TO LIPID | 17 | 888 | 7.409e-10 | 3.591e-08 |
| 97 | POSITIVE REGULATION OF PROTEOLYSIS | 12 | 363 | 8.354e-10 | 4.007e-08 |
| 98 | CELL PROLIFERATION | 15 | 672 | 1.13e-09 | 5.332e-08 |
| 99 | POSITIVE REGULATION OF CYCLIN DEPENDENT PROTEIN KINASE ACTIVITY | 6 | 36 | 1.134e-09 | 5.332e-08 |
| 100 | RESPONSE TO ORGANIC CYCLIC COMPOUND | 17 | 917 | 1.208e-09 | 5.619e-08 |
| 101 | REGULATION OF SISTER CHROMATID SEGREGATION | 7 | 67 | 1.298e-09 | 5.978e-08 |
| 102 | POSITIVE REGULATION OF CELL CYCLE PHASE TRANSITION | 7 | 68 | 1.443e-09 | 6.583e-08 |
| 103 | REGULATION OF NUCLEAR DIVISION | 9 | 163 | 1.533e-09 | 6.927e-08 |
| 104 | POSITIVE REGULATION OF CATALYTIC ACTIVITY | 21 | 1518 | 1.694e-09 | 7.579e-08 |
| 105 | DNA REPAIR | 13 | 480 | 1.714e-09 | 7.597e-08 |
| 106 | REGULATION OF MEMBRANE PERMEABILITY | 7 | 70 | 1.776e-09 | 7.796e-08 |
| 107 | PROTEIN PHOSPHORYLATION | 17 | 944 | 1.874e-09 | 8.149e-08 |
| 108 | REGULATION OF CELL GROWTH | 12 | 391 | 1.937e-09 | 8.343e-08 |
| 109 | RESPONSE TO OXYGEN LEVELS | 11 | 311 | 2.256e-09 | 9.632e-08 |
| 110 | POSITIVE REGULATION OF APOPTOTIC SIGNALING PATHWAY | 9 | 171 | 2.341e-09 | 9.903e-08 |
| 111 | RESPONSE TO STEROID HORMONE | 13 | 497 | 2.608e-09 | 1.093e-07 |
| 112 | INTRACELLULAR SIGNAL TRANSDUCTION | 21 | 1572 | 3.175e-09 | 1.319e-07 |
| 113 | REGULATION OF CATABOLIC PROCESS | 15 | 731 | 3.55e-09 | 1.462e-07 |
| 114 | POSITIVE REGULATION OF MITOTIC CELL CYCLE | 8 | 123 | 3.646e-09 | 1.488e-07 |
| 115 | NEGATIVE REGULATION OF CELL DEATH | 16 | 872 | 4.776e-09 | 1.933e-07 |
| 116 | RESPONSE TO ENDOGENOUS STIMULUS | 20 | 1450 | 4.955e-09 | 1.988e-07 |
| 117 | CELLULAR RESPONSE TO ENDOGENOUS STIMULUS | 17 | 1008 | 5.022e-09 | 1.997e-07 |
| 118 | POSITIVE REGULATION OF MOLECULAR FUNCTION | 22 | 1791 | 5.555e-09 | 2.191e-07 |
| 119 | REGULATION OF DNA METABOLIC PROCESS | 11 | 340 | 5.713e-09 | 2.234e-07 |
| 120 | RESPONSE TO DRUG | 12 | 431 | 5.777e-09 | 2.24e-07 |
| 121 | RESPONSE TO HORMONE | 16 | 893 | 6.697e-09 | 2.575e-07 |
| 122 | REGULATION OF CHROMOSOME SEGREGATION | 7 | 85 | 7.057e-09 | 2.692e-07 |
| 123 | CHROMOSOME SEGREGATION | 10 | 272 | 8.988e-09 | 3.373e-07 |
| 124 | POSITIVE REGULATION OF STEM CELL DIFFERENTIATION | 6 | 50 | 8.954e-09 | 3.373e-07 |
| 125 | REGULATION OF CELLULAR PROTEIN CATABOLIC PROCESS | 10 | 274 | 9.638e-09 | 3.588e-07 |
| 126 | NEGATIVE REGULATION OF NITROGEN COMPOUND METABOLIC PROCESS | 20 | 1517 | 1.07e-08 | 3.95e-07 |
| 127 | RESPONSE TO LIGHT STIMULUS | 10 | 280 | 1.184e-08 | 4.34e-07 |
| 128 | MITOCHONDRIAL MEMBRANE ORGANIZATION | 7 | 92 | 1.232e-08 | 4.478e-07 |
| 129 | DNA REPLICATION | 9 | 208 | 1.3e-08 | 4.689e-07 |
| 130 | REGULATION OF RESPONSE TO DNA DAMAGE STIMULUS | 8 | 145 | 1.338e-08 | 4.79e-07 |
| 131 | REGULATION OF EPITHELIAL CELL PROLIFERATION | 10 | 285 | 1.401e-08 | 4.978e-07 |
| 132 | REGULATION OF PROTEASOMAL UBIQUITIN DEPENDENT PROTEIN CATABOLIC PROCESS | 8 | 148 | 1.572e-08 | 5.54e-07 |
| 133 | APOPTOTIC SIGNALING PATHWAY | 10 | 289 | 1.6e-08 | 5.596e-07 |
| 134 | REGULATION OF TRANSCRIPTION INVOLVED IN G1 S TRANSITION OF MITOTIC CELL CYCLE | 5 | 27 | 1.712e-08 | 5.944e-07 |
| 135 | INTRINSIC APOPTOTIC SIGNALING PATHWAY | 8 | 152 | 1.937e-08 | 6.676e-07 |
| 136 | REGULATION OF PROTEIN LOCALIZATION TO NUCLEUS | 9 | 218 | 1.954e-08 | 6.684e-07 |
| 137 | POSITIVE REGULATION OF KINASE ACTIVITY | 12 | 482 | 1.999e-08 | 6.789e-07 |
| 138 | NEGATIVE REGULATION OF CHROMOSOME SEGREGATION | 5 | 28 | 2.079e-08 | 7.01e-07 |
| 139 | REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT | 9 | 220 | 2.114e-08 | 7.077e-07 |
| 140 | REGULATION OF CELLULAR LOCALIZATION | 18 | 1277 | 2.607e-08 | 8.666e-07 |
| 141 | NUCLEAR CHROMOSOME SEGREGATION | 9 | 228 | 2.878e-08 | 9.499e-07 |
| 142 | REPLICATIVE SENESCENCE | 4 | 12 | 3.806e-08 | 1.247e-06 |
| 143 | NEGATIVE REGULATION OF PROTEIN CATABOLIC PROCESS | 7 | 109 | 4.025e-08 | 1.31e-06 |
| 144 | REGULATION OF GROWTH | 13 | 633 | 4.596e-08 | 1.485e-06 |
| 145 | NEGATIVE REGULATION OF CELL GROWTH | 8 | 170 | 4.637e-08 | 1.488e-06 |
| 146 | REGULATION OF CELL AGING | 5 | 33 | 4.962e-08 | 1.581e-06 |
| 147 | MITOTIC CELL CYCLE ARREST | 4 | 13 | 5.485e-08 | 1.736e-06 |
| 148 | NEGATIVE REGULATION OF EPITHELIAL CELL PROLIFERATION | 7 | 115 | 5.835e-08 | 1.822e-06 |
| 149 | POSITIVE REGULATION OF EPITHELIAL TO MESENCHYMAL TRANSITION | 5 | 34 | 5.804e-08 | 1.822e-06 |
| 150 | SISTER CHROMATID SEGREGATION | 8 | 176 | 6.069e-08 | 1.882e-06 |
| 151 | REGULATION OF PROTEASOMAL PROTEIN CATABOLIC PROCESS | 8 | 181 | 7.538e-08 | 2.323e-06 |
| 152 | INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO DNA DAMAGE | 6 | 71 | 7.68e-08 | 2.351e-06 |
| 153 | POSITIVE REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT | 7 | 121 | 8.29e-08 | 2.521e-06 |
| 154 | PHOSPHORYLATION | 17 | 1228 | 9.142e-08 | 2.762e-06 |
| 155 | REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION TO MITOCHONDRION | 7 | 128 | 1.221e-07 | 3.664e-06 |
| 156 | POSITIVE REGULATION OF PROTEIN LOCALIZATION TO NUCLEUS | 7 | 129 | 1.288e-07 | 3.841e-06 |
| 157 | REGULATION OF APOPTOTIC SIGNALING PATHWAY | 10 | 363 | 1.358e-07 | 4.025e-06 |
| 158 | CELLULAR RESPONSE TO ORGANIC CYCLIC COMPOUND | 11 | 465 | 1.399e-07 | 4.119e-06 |
| 159 | NEGATIVE REGULATION OF CELL AGING | 4 | 17 | 1.809e-07 | 5.294e-06 |
| 160 | REGULATION OF TRANSMEMBRANE RECEPTOR PROTEIN SERINE THREONINE KINASE SIGNALING PATHWAY | 8 | 207 | 2.116e-07 | 6.154e-06 |
| 161 | REGULATION OF RESPONSE TO STRESS | 18 | 1468 | 2.155e-07 | 6.229e-06 |
| 162 | POSITIVE REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 9 | 289 | 2.179e-07 | 6.258e-06 |
| 163 | RESPONSE TO NITROGEN COMPOUND | 14 | 859 | 2.243e-07 | 6.402e-06 |
| 164 | REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY | 8 | 213 | 2.632e-07 | 7.468e-06 |
| 165 | RHYTHMIC PROCESS | 9 | 298 | 2.822e-07 | 7.958e-06 |
| 166 | RESPONSE TO IONIZING RADIATION | 7 | 145 | 2.863e-07 | 8.026e-06 |
| 167 | GLAND DEVELOPMENT | 10 | 395 | 2.963e-07 | 8.255e-06 |
| 168 | REGULATION OF MITOCHONDRION ORGANIZATION | 8 | 218 | 3.142e-07 | 8.65e-06 |
| 169 | RESPONSE TO ESTROGEN | 8 | 218 | 3.142e-07 | 8.65e-06 |
| 170 | DIGESTIVE SYSTEM DEVELOPMENT | 7 | 148 | 3.291e-07 | 9.008e-06 |
| 171 | POSITIVE REGULATION OF CHROMOSOME ORGANIZATION | 7 | 150 | 3.605e-07 | 9.81e-06 |
| 172 | POSITIVE REGULATION OF FIBROBLAST PROLIFERATION | 5 | 53 | 5.726e-07 | 1.543e-05 |
| 173 | NEGATIVE REGULATION OF GROWTH | 8 | 236 | 5.737e-07 | 1.543e-05 |
| 174 | REGULATION OF DNA REPLICATION | 7 | 161 | 5.822e-07 | 1.557e-05 |
| 175 | POSITIVE REGULATION OF TRANSMEMBRANE RECEPTOR PROTEIN SERINE THREONINE KINASE SIGNALING PATHWAY | 6 | 100 | 5.969e-07 | 1.587e-05 |
| 176 | REGULATION OF SIGNAL TRANSDUCTION BY P53 CLASS MEDIATOR | 7 | 162 | 6.07e-07 | 1.596e-05 |
| 177 | POSITIVE REGULATION OF CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION | 7 | 162 | 6.07e-07 | 1.596e-05 |
| 178 | POSITIVE REGULATION OF TRANSPORT | 14 | 936 | 6.319e-07 | 1.652e-05 |
| 179 | NEGATIVE REGULATION OF PROTEOLYSIS | 9 | 329 | 6.466e-07 | 1.681e-05 |
| 180 | NEGATIVE REGULATION OF DEVELOPMENTAL PROCESS | 13 | 801 | 6.853e-07 | 1.771e-05 |
| 181 | EPITHELIUM DEVELOPMENT | 14 | 945 | 7.086e-07 | 1.822e-05 |
| 182 | POSITIVE REGULATION OF MITOCHONDRION ORGANIZATION | 7 | 167 | 7.451e-07 | 1.905e-05 |
| 183 | CELLULAR RESPONSE TO REACTIVE OXYGEN SPECIES | 6 | 104 | 7.527e-07 | 1.914e-05 |
| 184 | REGULATION OF CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION | 9 | 337 | 7.897e-07 | 1.997e-05 |
| 185 | PHOSPHATE CONTAINING COMPOUND METABOLIC PROCESS | 20 | 1977 | 8.336e-07 | 2.097e-05 |
| 186 | SPINDLE CHECKPOINT | 4 | 25 | 9.442e-07 | 2.349e-05 |
| 187 | POSITIVE REGULATION OF CHROMOSOME SEGREGATION | 4 | 25 | 9.442e-07 | 2.349e-05 |
| 188 | NEGATIVE REGULATION OF CELL DIVISION | 5 | 60 | 1.072e-06 | 2.653e-05 |
| 189 | MITOCHONDRIAL TRANSPORT | 7 | 177 | 1.101e-06 | 2.706e-05 |
| 190 | SISTER CHROMATID COHESION | 6 | 111 | 1.105e-06 | 2.706e-05 |
| 191 | REGULATION OF CELLULAR SENESCENCE | 4 | 26 | 1.113e-06 | 2.712e-05 |
| 192 | CELLULAR RESPONSE TO HYDROGEN PEROXIDE | 5 | 61 | 1.165e-06 | 2.824e-05 |
| 193 | POSITIVE REGULATION OF DEVELOPMENTAL PROCESS | 15 | 1142 | 1.202e-06 | 2.898e-05 |
| 194 | REGULATION OF STEM CELL DIFFERENTIATION | 6 | 113 | 1.227e-06 | 2.943e-05 |
| 195 | SOMITOGENESIS | 5 | 62 | 1.264e-06 | 3.017e-05 |
| 196 | CELLULAR RESPONSE TO ORGANIC SUBSTANCE | 19 | 1848 | 1.356e-06 | 3.212e-05 |
| 197 | PROTEIN SUMOYLATION | 6 | 115 | 1.36e-06 | 3.212e-05 |
| 198 | REGULATION OF CELL DIFFERENTIATION | 17 | 1492 | 1.43e-06 | 3.343e-05 |
| 199 | RESPONSE TO ALCOHOL | 9 | 362 | 1.428e-06 | 3.343e-05 |
| 200 | NEGATIVE REGULATION OF GENE EXPRESSION | 17 | 1493 | 1.443e-06 | 3.357e-05 |
| 201 | POSITIVE REGULATION OF DNA METABOLIC PROCESS | 7 | 185 | 1.48e-06 | 3.399e-05 |
| 202 | NEGATIVE REGULATION OF CELLULAR PROTEIN CATABOLIC PROCESS | 5 | 64 | 1.483e-06 | 3.399e-05 |
| 203 | POSITIVE REGULATION OF RESPONSE TO DNA DAMAGE STIMULUS | 5 | 64 | 1.483e-06 | 3.399e-05 |
| 204 | REGULATION OF DNA DAMAGE RESPONSE SIGNAL TRANSDUCTION BY P53 CLASS MEDIATOR | 4 | 28 | 1.518e-06 | 3.462e-05 |
| 205 | MEIOTIC CELL CYCLE | 7 | 186 | 1.534e-06 | 3.483e-05 |
| 206 | DNA REPLICATION INITIATION | 4 | 29 | 1.757e-06 | 3.968e-05 |
| 207 | REGULATION OF CYTOPLASMIC TRANSPORT | 10 | 481 | 1.772e-06 | 3.984e-05 |
| 208 | TISSUE DEVELOPMENT | 17 | 1518 | 1.814e-06 | 4.057e-05 |
| 209 | REGULATION OF EPITHELIAL TO MESENCHYMAL TRANSITION | 5 | 67 | 1.865e-06 | 4.152e-05 |
| 210 | POSITIVE REGULATION OF CYTOPLASMIC TRANSPORT | 8 | 282 | 2.181e-06 | 4.809e-05 |
| 211 | REGULATION OF INTRACELLULAR PROTEIN TRANSPORT | 9 | 381 | 2.175e-06 | 4.809e-05 |
| 212 | REGULATION OF BINDING | 8 | 283 | 2.239e-06 | 4.914e-05 |
| 213 | RESPONSE TO OXYGEN CONTAINING COMPOUND | 16 | 1381 | 2.548e-06 | 5.567e-05 |
| 214 | NEGATIVE REGULATION OF CYCLIN DEPENDENT PROTEIN KINASE ACTIVITY | 4 | 32 | 2.641e-06 | 5.743e-05 |
| 215 | CELLULAR RESPONSE TO NITROGEN COMPOUND | 10 | 505 | 2.738e-06 | 5.913e-05 |
| 216 | NEGATIVE REGULATION OF CATABOLIC PROCESS | 7 | 203 | 2.745e-06 | 5.913e-05 |
| 217 | REGULATION OF LIGASE ACTIVITY | 6 | 130 | 2.782e-06 | 5.966e-05 |
| 218 | REGULATION OF PROTEIN EXPORT FROM NUCLEUS | 4 | 33 | 2.999e-06 | 6.372e-05 |
| 219 | G2 DNA DAMAGE CHECKPOINT | 4 | 33 | 2.999e-06 | 6.372e-05 |
| 220 | POSITIVE REGULATION OF CELL DIVISION | 6 | 132 | 3.04e-06 | 6.43e-05 |
| 221 | PROTEIN DESTABILIZATION | 4 | 34 | 3.391e-06 | 7.108e-05 |
| 222 | NEGATIVE REGULATION OF MITOTIC NUCLEAR DIVISION | 4 | 34 | 3.391e-06 | 7.108e-05 |
| 223 | REGULATION OF CELLULAR RESPONSE TO HEAT | 5 | 76 | 3.494e-06 | 7.29e-05 |
| 224 | RESPONSE TO MINERALOCORTICOID | 4 | 35 | 3.82e-06 | 7.935e-05 |
| 225 | SOMITE DEVELOPMENT | 5 | 78 | 3.974e-06 | 8.218e-05 |
| 226 | NEGATIVE REGULATION OF CELLULAR SENESCENCE | 3 | 11 | 4.378e-06 | 8.973e-05 |
| 227 | ACTIVATION OF MAPKKK ACTIVITY | 3 | 11 | 4.378e-06 | 8.973e-05 |
| 228 | PEPTIDYL LYSINE MODIFICATION | 8 | 312 | 4.605e-06 | 9.398e-05 |
| 229 | REGULATION OF FIBROBLAST PROLIFERATION | 5 | 81 | 4.789e-06 | 9.728e-05 |
| 230 | REGULATION OF PROTEIN STABILITY | 7 | 221 | 4.809e-06 | 9.728e-05 |
| 231 | MESENCHYME MORPHOGENESIS | 4 | 38 | 5.349e-06 | 0.0001077 |
| 232 | PEPTIDYL SERINE MODIFICATION | 6 | 148 | 5.89e-06 | 0.0001179 |
| 233 | REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 17 | 1656 | 5.906e-06 | 0.0001179 |
| 234 | CELLULAR RESPONSE TO HORMONE STIMULUS | 10 | 552 | 6.015e-06 | 0.0001196 |
| 235 | POSITIVE REGULATION OF DNA REPLICATION | 5 | 86 | 6.434e-06 | 0.0001274 |
| 236 | REGULATION OF MULTICELLULAR ORGANISMAL DEVELOPMENT | 17 | 1672 | 6.717e-06 | 0.0001324 |
| 237 | MEIOTIC CELL CYCLE PROCESS | 6 | 152 | 6.866e-06 | 0.0001348 |
| 238 | MEIOSIS I | 5 | 88 | 7.204e-06 | 0.0001408 |
| 239 | POSITIVE REGULATION OF DNA DAMAGE RESPONSE SIGNAL TRANSDUCTION BY P53 CLASS MEDIATOR | 3 | 13 | 7.555e-06 | 0.0001471 |
| 240 | SEGMENTATION | 5 | 89 | 7.615e-06 | 0.0001476 |
| 241 | REGULATION OF MICROTUBULE BASED PROCESS | 7 | 243 | 8.948e-06 | 0.0001728 |
| 242 | POSITIVE REGULATION OF MITOTIC SISTER CHROMATID SEPARATION | 3 | 14 | 9.594e-06 | 0.0001815 |
| 243 | POSITIVE REGULATION OF MITOTIC METAPHASE ANAPHASE TRANSITION | 3 | 14 | 9.594e-06 | 0.0001815 |
| 244 | IMMUNE SYSTEM DEVELOPMENT | 10 | 582 | 9.556e-06 | 0.0001815 |
| 245 | POSITIVE REGULATION OF P38MAPK CASCADE | 3 | 14 | 9.594e-06 | 0.0001815 |
| 246 | POSITIVE REGULATION OF METAPHASE ANAPHASE TRANSITION OF CELL CYCLE | 3 | 14 | 9.594e-06 | 0.0001815 |
| 247 | REGULATION OF DNA BIOSYNTHETIC PROCESS | 5 | 94 | 9.954e-06 | 0.0001875 |
| 248 | PROTEIN LOCALIZATION TO CHROMOSOME | 4 | 45 | 1.063e-05 | 0.0001994 |
| 249 | NEGATIVE REGULATION OF CHROMOSOME ORGANIZATION | 5 | 96 | 1.103e-05 | 0.0002062 |
| 250 | NEGATIVE REGULATION OF NUCLEAR DIVISION | 4 | 46 | 1.161e-05 | 0.0002161 |
| 251 | ACTIVATION OF ANAPHASE PROMOTING COMPLEX ACTIVITY | 3 | 15 | 1.197e-05 | 0.0002218 |
| 252 | POSITIVE REGULATION OF PROTEASOMAL PROTEIN CATABOLIC PROCESS | 5 | 98 | 1.22e-05 | 0.0002253 |
| 253 | DNA DEPENDENT DNA REPLICATION | 5 | 99 | 1.282e-05 | 0.000233 |
| 254 | REGULATION OF TRANSFORMING GROWTH FACTOR BETA RECEPTOR SIGNALING PATHWAY | 5 | 99 | 1.282e-05 | 0.000233 |
| 255 | REGULATION OF CELLULAR RESPONSE TO TRANSFORMING GROWTH FACTOR BETA STIMULUS | 5 | 99 | 1.282e-05 | 0.000233 |
| 256 | NEGATIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 11 | 740 | 1.276e-05 | 0.000233 |
| 257 | RESPONSE TO GROWTH FACTOR | 9 | 475 | 1.292e-05 | 0.0002339 |
| 258 | POSITIVE REGULATION OF INTRACELLULAR PROTEIN TRANSPORT | 7 | 258 | 1.32e-05 | 0.0002381 |
| 259 | RESPONSE TO INORGANIC SUBSTANCE | 9 | 479 | 1.381e-05 | 0.0002471 |
| 260 | POSITIVE REGULATION OF PATHWAY RESTRICTED SMAD PROTEIN PHOSPHORYLATION | 4 | 48 | 1.378e-05 | 0.0002471 |
| 261 | CELLULAR RESPONSE TO ANTIBIOTIC | 3 | 16 | 1.47e-05 | 0.000262 |
| 262 | POSITIVE REGULATION OF PROTEIN CATABOLIC PROCESS | 7 | 263 | 1.494e-05 | 0.0002654 |
| 263 | CELLULAR RESPONSE TO EXTERNAL STIMULUS | 7 | 264 | 1.532e-05 | 0.0002699 |
| 264 | AGING | 7 | 264 | 1.532e-05 | 0.0002699 |
| 265 | RESPONSE TO GAMMA RADIATION | 4 | 50 | 1.624e-05 | 0.0002851 |
| 266 | REGULATION OF MICROTUBULE POLYMERIZATION OR DEPOLYMERIZATION | 6 | 178 | 1.69e-05 | 0.0002957 |
| 267 | POSITIVE REGULATION OF SIGNAL TRANSDUCTION BY P53 CLASS MEDIATOR | 3 | 17 | 1.781e-05 | 0.0003092 |
| 268 | REGULATION OF SISTER CHROMATID COHESION | 3 | 17 | 1.781e-05 | 0.0003092 |
| 269 | CELL DEVELOPMENT | 15 | 1426 | 1.8e-05 | 0.0003114 |
| 270 | CELLULAR RESPONSE TO IONIZING RADIATION | 4 | 52 | 1.9e-05 | 0.0003274 |
| 271 | RESPONSE TO KETONE | 6 | 182 | 1.917e-05 | 0.0003291 |
| 272 | REGULATION OF PROTEIN IMPORT | 6 | 183 | 1.977e-05 | 0.0003382 |
| 273 | REGULATION OF CYTOSKELETON ORGANIZATION | 9 | 502 | 2.001e-05 | 0.0003411 |
| 274 | CELLULAR RESPONSE TO OXIDATIVE STRESS | 6 | 184 | 2.039e-05 | 0.0003461 |
| 275 | RESPONSE TO HYDROGEN PEROXIDE | 5 | 109 | 2.046e-05 | 0.0003461 |
| 276 | REGULATION OF PROTEIN MODIFICATION BY SMALL PROTEIN CONJUGATION OR REMOVAL | 7 | 280 | 2.236e-05 | 0.0003757 |
| 277 | NEGATIVE REGULATION OF DNA METABOLIC PROCESS | 5 | 111 | 2.234e-05 | 0.0003757 |
| 278 | NEGATIVE REGULATION OF DNA REPLICATION | 4 | 55 | 2.377e-05 | 0.0003979 |
| 279 | REGULATION OF PEPTIDASE ACTIVITY | 8 | 392 | 2.41e-05 | 0.0004019 |
| 280 | RESPONSE TO REACTIVE OXYGEN SPECIES | 6 | 191 | 2.517e-05 | 0.0004183 |
| 281 | POSITIVE REGULATION OF PROTEIN EXPORT FROM NUCLEUS | 3 | 19 | 2.526e-05 | 0.0004183 |
| 282 | NOTCH SIGNALING PATHWAY | 5 | 114 | 2.541e-05 | 0.0004192 |
| 283 | SMAD PROTEIN SIGNAL TRANSDUCTION | 4 | 56 | 2.554e-05 | 0.00042 |
| 284 | POSITIVE REGULATION OF CELLULAR PROTEIN CATABOLIC PROCESS | 6 | 192 | 2.592e-05 | 0.0004247 |
| 285 | REPRODUCTION | 14 | 1297 | 2.739e-05 | 0.0004471 |
| 286 | POSITIVE REGULATION OF DNA BIOSYNTHETIC PROCESS | 4 | 59 | 3.144e-05 | 0.0005097 |
| 287 | REGULATION OF CELL CYCLE G2 M PHASE TRANSITION | 4 | 59 | 3.144e-05 | 0.0005097 |
| 288 | REGULATION OF PATHWAY RESTRICTED SMAD PROTEIN PHOSPHORYLATION | 4 | 60 | 3.361e-05 | 0.000543 |
| 289 | POSITIVE REGULATION OF CELL DIFFERENTIATION | 11 | 823 | 3.408e-05 | 0.0005487 |
| 290 | CHROMATIN MODIFICATION | 9 | 539 | 3.495e-05 | 0.0005607 |
| 291 | NEGATIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION | 10 | 684 | 3.822e-05 | 0.0006111 |
| 292 | ENDOCARDIAL CUSHION MORPHOGENESIS | 3 | 22 | 3.989e-05 | 0.0006357 |
| 293 | REGULATION OF PROTEIN TARGETING | 7 | 307 | 4.023e-05 | 0.0006389 |
| 294 | REGULATION OF CELL MORPHOGENESIS | 9 | 552 | 4.206e-05 | 0.0006657 |
| 295 | POSITIVE REGULATION OF MULTICELLULAR ORGANISMAL METABOLIC PROCESS | 3 | 23 | 4.578e-05 | 0.0007196 |
| 296 | POSITIVE REGULATION OF COLLAGEN METABOLIC PROCESS | 3 | 23 | 4.578e-05 | 0.0007196 |
| 297 | NEGATIVE REGULATION OF RESPONSE TO STIMULUS | 14 | 1360 | 4.617e-05 | 0.0007234 |
| 298 | REGULATION OF CYTOKINE PRODUCTION | 9 | 563 | 4.901e-05 | 0.0007652 |
| 299 | POSITIVE REGULATION OF NEURON DEATH | 4 | 67 | 5.199e-05 | 0.0008016 |
| 300 | POSITIVE REGULATION OF CELLULAR RESPONSE TO TRANSFORMING GROWTH FACTOR BETA STIMULUS | 3 | 24 | 5.22e-05 | 0.0008016 |
| 301 | POSITIVE REGULATION OF G1 S TRANSITION OF MITOTIC CELL CYCLE | 3 | 24 | 5.22e-05 | 0.0008016 |
| 302 | POSITIVE REGULATION OF TRANSFORMING GROWTH FACTOR BETA RECEPTOR SIGNALING PATHWAY | 3 | 24 | 5.22e-05 | 0.0008016 |
| 303 | CELL AGING | 4 | 67 | 5.199e-05 | 0.0008016 |
| 304 | CELL ACTIVATION | 9 | 568 | 5.247e-05 | 0.0008032 |
| 305 | CELLULAR RESPONSE TO STEROID HORMONE STIMULUS | 6 | 218 | 5.273e-05 | 0.0008045 |
| 306 | RESPONSE TO ETHANOL | 5 | 136 | 5.918e-05 | 0.0008942 |
| 307 | CELLULAR RESPONSE TO TOXIC SUBSTANCE | 3 | 25 | 5.919e-05 | 0.0008942 |
| 308 | REGULATION OF TRANSFORMING GROWTH FACTOR BETA PRODUCTION | 3 | 25 | 5.919e-05 | 0.0008942 |
| 309 | POSITIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 11 | 876 | 6.003e-05 | 0.0009039 |
| 310 | POSITIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS | 14 | 1395 | 6.089e-05 | 0.000914 |
| 311 | INTRACELLULAR STEROID HORMONE RECEPTOR SIGNALING PATHWAY | 4 | 71 | 6.531e-05 | 0.0009771 |
| 312 | RESPONSE TO CORTICOSTERONE | 3 | 26 | 6.677e-05 | 0.0009925 |
| 313 | REGULATION OF P38MAPK CASCADE | 3 | 26 | 6.677e-05 | 0.0009925 |
| 314 | RESPONSE TO METAL ION | 7 | 333 | 6.719e-05 | 0.0009956 |
| 315 | REGULATION OF CELLULAR RESPONSE TO GROWTH FACTOR STIMULUS | 6 | 229 | 6.927e-05 | 0.001023 |
| 316 | CELLULAR RESPONSE TO LIPID | 8 | 457 | 7.122e-05 | 0.001049 |
| 317 | REGULATION OF TRANSPORT | 16 | 1804 | 7.203e-05 | 0.001054 |
| 318 | CELLULAR MACROMOLECULE LOCALIZATION | 13 | 1234 | 7.188e-05 | 0.001054 |
| 319 | RESPONSE TO TRANSFORMING GROWTH FACTOR BETA | 5 | 144 | 7.763e-05 | 0.001132 |
| 320 | LYMPHOCYTE ACTIVATION | 7 | 342 | 7.94e-05 | 0.001155 |
| 321 | HEART DEVELOPMENT | 8 | 466 | 8.158e-05 | 0.001183 |
| 322 | RESPONSE TO ESTRADIOL | 5 | 146 | 8.287e-05 | 0.001198 |
| 323 | NEGATIVE REGULATION OF DENDRITE DEVELOPMENT | 3 | 28 | 8.376e-05 | 0.001207 |
| 324 | MICROTUBULE CYTOSKELETON ORGANIZATION | 7 | 348 | 8.851e-05 | 0.001271 |
| 325 | NEGATIVE REGULATION OF CELL DIFFERENTIATION | 9 | 609 | 8.955e-05 | 0.001282 |
| 326 | NEGATIVE REGULATION OF PRODUCTION OF MOLECULAR MEDIATOR OF IMMUNE RESPONSE | 3 | 29 | 9.322e-05 | 0.001318 |
| 327 | REGULATION OF EXTRACELLULAR MATRIX ORGANIZATION | 3 | 29 | 9.322e-05 | 0.001318 |
| 328 | REGULATION OF HEART MORPHOGENESIS | 3 | 29 | 9.322e-05 | 0.001318 |
| 329 | POSITIVE REGULATION OF CELL CYCLE G1 S PHASE TRANSITION | 3 | 29 | 9.322e-05 | 0.001318 |
| 330 | REGULATION OF CELLULAR COMPONENT BIOGENESIS | 10 | 767 | 9.947e-05 | 0.001403 |
| 331 | NEGATIVE REGULATION OF CELLULAR CATABOLIC PROCESS | 5 | 156 | 0.0001133 | 0.001592 |
| 332 | ORGAN REGENERATION | 4 | 83 | 0.0001202 | 0.001683 |
| 333 | SENSORY ORGAN DEVELOPMENT | 8 | 493 | 0.0001205 | 0.001683 |
| 334 | EPITHELIAL CELL DIFFERENTIATION | 8 | 495 | 0.0001239 | 0.001726 |
| 335 | ENDOCARDIAL CUSHION DEVELOPMENT | 3 | 32 | 0.0001257 | 0.001746 |
| 336 | NEGATIVE REGULATION OF IMMUNE SYSTEM PROCESS | 7 | 372 | 0.0001339 | 0.001854 |
| 337 | OVULATION CYCLE PROCESS | 4 | 88 | 0.0001508 | 0.002073 |
| 338 | NEGATIVE REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY | 4 | 88 | 0.0001508 | 0.002073 |
| 339 | HEART VALVE DEVELOPMENT | 3 | 34 | 0.000151 | 0.002073 |
| 340 | B CELL DIFFERENTIATION | 4 | 89 | 0.0001575 | 0.002156 |
| 341 | REGULATION OF CELL MATRIX ADHESION | 4 | 90 | 0.0001645 | 0.002236 |
| 342 | RESPONSE TO IRON ION | 3 | 35 | 0.0001648 | 0.002236 |
| 343 | RESPONSE TO MONOAMINE | 3 | 35 | 0.0001648 | 0.002236 |
| 344 | CHROMATIN ORGANIZATION | 9 | 663 | 0.0001701 | 0.0023 |
| 345 | MITOTIC SISTER CHROMATID SEGREGATION | 4 | 91 | 0.0001717 | 0.002315 |
| 346 | POSITIVE REGULATION OF CATABOLIC PROCESS | 7 | 395 | 0.0001936 | 0.002604 |
| 347 | REGULATION OF CELL DEVELOPMENT | 10 | 836 | 0.0002009 | 0.002694 |
| 348 | TRANSFORMING GROWTH FACTOR BETA RECEPTOR SIGNALING PATHWAY | 4 | 95 | 0.0002026 | 0.002709 |
| 349 | ACTIVATION OF PROTEIN KINASE ACTIVITY | 6 | 279 | 0.0002038 | 0.002717 |
| 350 | ORGAN MORPHOGENESIS | 10 | 841 | 0.0002108 | 0.002798 |
| 351 | REGULATION OF MULTICELLULAR ORGANISMAL METABOLIC PROCESS | 3 | 38 | 0.0002111 | 0.002798 |
| 352 | NEGATIVE REGULATION OF CELL COMMUNICATION | 12 | 1192 | 0.0002182 | 0.002885 |
| 353 | RESPONSE TO PEPTIDE | 7 | 404 | 0.0002222 | 0.002929 |
| 354 | HEMATOPOIETIC PROGENITOR CELL DIFFERENTIATION | 4 | 98 | 0.0002283 | 0.002976 |
| 355 | POSITIVE REGULATION OF CELLULAR COMPONENT BIOGENESIS | 7 | 406 | 0.000229 | 0.002976 |
| 356 | CELLULAR RESPONSE TO NUTRIENT | 3 | 39 | 0.0002282 | 0.002976 |
| 357 | RESPONSE TO VITAMIN | 4 | 98 | 0.0002283 | 0.002976 |
| 358 | SPLEEN DEVELOPMENT | 3 | 39 | 0.0002282 | 0.002976 |
| 359 | GROWTH | 7 | 410 | 0.000243 | 0.00315 |
| 360 | POSITIVE REGULATION OF CELL MATRIX ADHESION | 3 | 40 | 0.0002461 | 0.003172 |
| 361 | REGULATION OF SMOOTH MUSCLE CELL PROLIFERATION | 4 | 100 | 0.0002468 | 0.003172 |
| 362 | RESPONSE TO CADMIUM ION | 3 | 40 | 0.0002461 | 0.003172 |
| 363 | LEUKOCYTE ACTIVATION | 7 | 414 | 0.0002578 | 0.003296 |
| 364 | NEUROGENESIS | 13 | 1402 | 0.0002574 | 0.003296 |
| 365 | REGULATION OF IMMUNE SYSTEM PROCESS | 13 | 1403 | 0.0002592 | 0.003304 |
| 366 | TUBE DEVELOPMENT | 8 | 552 | 0.0002603 | 0.003309 |
| 367 | ANDROGEN RECEPTOR SIGNALING PATHWAY | 3 | 41 | 0.000265 | 0.003359 |
| 368 | CELLULAR RESPONSE TO EXTRACELLULAR STIMULUS | 5 | 188 | 0.0002703 | 0.003417 |
| 369 | PROTEIN LOCALIZATION TO ORGANELLE | 8 | 556 | 0.0002733 | 0.003446 |
| 370 | MESENCHYME DEVELOPMENT | 5 | 190 | 0.0002838 | 0.003569 |
| 371 | POSITIVE REGULATION OF PROTEIN IMPORT | 4 | 104 | 0.0002867 | 0.003596 |
| 372 | RESPONSE TO EXTERNAL STIMULUS | 15 | 1821 | 0.0002897 | 0.003624 |
| 373 | RESPONSE TO NUTRIENT | 5 | 191 | 0.0002907 | 0.003627 |
| 374 | BETA CATENIN TCF COMPLEX ASSEMBLY | 3 | 43 | 0.0003054 | 0.0038 |
| 375 | ANTERIOR POSTERIOR PATTERN SPECIFICATION | 5 | 194 | 0.0003124 | 0.003876 |
| 376 | TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 9 | 724 | 0.0003265 | 0.00404 |
| 377 | POSITIVE REGULATION OF PROTEIN MODIFICATION BY SMALL PROTEIN CONJUGATION OR REMOVAL | 5 | 196 | 0.0003274 | 0.004041 |
| 378 | REGULATION OF STRESS ACTIVATED PROTEIN KINASE SIGNALING CASCADE | 5 | 197 | 0.0003352 | 0.004126 |
| 379 | EMBRYO DEVELOPMENT | 10 | 894 | 0.0003438 | 0.004221 |
| 380 | NEGATIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 7 | 437 | 0.0003574 | 0.004377 |
| 381 | RESPONSE TO EXTRACELLULAR STIMULUS | 7 | 441 | 0.0003775 | 0.004611 |
| 382 | OVULATION CYCLE | 4 | 113 | 0.0003934 | 0.004792 |
| 383 | RESPONSE TO ANTIBIOTIC | 3 | 47 | 0.0003978 | 0.004821 |
| 384 | POSITIVE REGULATION OF NEURON APOPTOTIC PROCESS | 3 | 47 | 0.0003978 | 0.004821 |
| 385 | HOMOLOGOUS CHROMOSOME SEGREGATION | 3 | 48 | 0.0004234 | 0.005118 |
| 386 | MITOCHONDRION ORGANIZATION | 8 | 594 | 0.0004252 | 0.005125 |
| 387 | LYMPHOCYTE DIFFERENTIATION | 5 | 209 | 0.0004394 | 0.005283 |
| 388 | EYE DEVELOPMENT | 6 | 326 | 0.000468 | 0.005612 |
| 389 | RESPONSE TO PROGESTERONE | 3 | 50 | 0.0004778 | 0.005715 |
| 390 | POSITIVE REGULATION OF MITOTIC NUCLEAR DIVISION | 3 | 51 | 0.0005065 | 0.006028 |
| 391 | RESPONSE TO AMMONIUM ION | 3 | 51 | 0.0005065 | 0.006028 |
| 392 | DEVELOPMENTAL GROWTH | 6 | 333 | 0.0005234 | 0.006213 |
| 393 | INTRINSIC APOPTOTIC SIGNALING PATHWAY BY P53 CLASS MEDIATOR | 3 | 53 | 0.0005673 | 0.0067 |
| 394 | POSITIVE REGULATION OF CELL DEVELOPMENT | 7 | 472 | 0.0005662 | 0.0067 |
| 395 | STEROID HORMONE MEDIATED SIGNALING PATHWAY | 4 | 125 | 0.0005762 | 0.006788 |
| 396 | REGULATION OF HYDROLASE ACTIVITY | 12 | 1327 | 0.000579 | 0.006803 |
| 397 | PROTEIN COMPLEX SUBUNIT ORGANIZATION | 13 | 1527 | 0.0005858 | 0.006866 |
| 398 | REGULATION OF MACROPHAGE CYTOKINE PRODUCTION | 2 | 12 | 0.0005922 | 0.006906 |
| 399 | POSITIVE REGULATION OF SMAD PROTEIN IMPORT INTO NUCLEUS | 2 | 12 | 0.0005922 | 0.006906 |
| 400 | REGULATION OF MITOCHONDRIAL MEMBRANE POTENTIAL | 3 | 54 | 0.0005994 | 0.006973 |
| 401 | POSITIVE REGULATION OF BINDING | 4 | 127 | 0.0006117 | 0.007098 |
| 402 | HEPATICOBILIARY SYSTEM DEVELOPMENT | 4 | 128 | 0.00063 | 0.007292 |
| 403 | REGULATION OF B CELL PROLIFERATION | 3 | 55 | 0.0006326 | 0.007304 |
| 404 | CELLULAR RESPONSE TO OXYGEN CONTAINING COMPOUND | 9 | 799 | 0.0006665 | 0.007663 |
| 405 | EPITHELIAL TO MESENCHYMAL TRANSITION | 3 | 56 | 0.000667 | 0.007663 |
| 406 | PROTEIN STABILIZATION | 4 | 131 | 0.0006872 | 0.007876 |
| 407 | PROTEIN LOCALIZATION TO CHROMATIN | 2 | 13 | 0.0006985 | 0.007983 |
| 408 | RESPONSE TO OXIDATIVE STRESS | 6 | 352 | 7e-04 | 0.007983 |
| 409 | B CELL ACTIVATION | 4 | 132 | 0.0007071 | 0.008044 |
| 410 | NEGATIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS | 10 | 983 | 0.0007225 | 0.008199 |
| 411 | POSITIVE REGULATION OF STRESS ACTIVATED PROTEIN KINASE SIGNALING CASCADE | 4 | 135 | 0.0007692 | 0.008708 |
| 412 | POSITIVE REGULATION OF GROWTH | 5 | 238 | 0.0007913 | 0.008937 |
| 413 | REGULATION OF SMOOTH MUSCLE CELL APOPTOTIC PROCESS | 2 | 14 | 0.0008133 | 0.009163 |
| 414 | RESPONSE TO TOXIC SUBSTANCE | 5 | 241 | 0.0008371 | 0.009408 |
| 415 | REGULATION OF MAPK CASCADE | 8 | 660 | 0.0008484 | 0.009513 |
| 416 | MEMBRANE DEPOLARIZATION | 3 | 61 | 0.0008567 | 0.009525 |
| 417 | NEGATIVE REGULATION OF PROTEIN MODIFICATION BY SMALL PROTEIN CONJUGATION OR REMOVAL | 4 | 139 | 0.0008578 | 0.009525 |
| 418 | EMBRYONIC DIGIT MORPHOGENESIS | 3 | 61 | 0.0008567 | 0.009525 |
| 419 | REGULATION OF ORGAN MORPHOGENESIS | 5 | 242 | 0.0008527 | 0.009525 |
| 420 | POSITIVE REGULATION OF NUCLEAR DIVISION | 3 | 62 | 0.0008983 | 0.009951 |
| Num | GO | Overlap | Size | P Value | Adj. P Value |
|---|---|---|---|---|---|
| 1 | CYCLIN DEPENDENT PROTEIN SERINE THREONINE KINASE REGULATOR ACTIVITY | 10 | 28 | 4.031e-19 | 3.745e-16 |
| 2 | KINASE BINDING | 21 | 606 | 3.596e-17 | 1.67e-14 |
| 3 | PROTEIN SERINE THREONINE KINASE INHIBITOR ACTIVITY | 9 | 30 | 1.677e-16 | 5.193e-14 |
| 4 | CYCLIN DEPENDENT PROTEIN SERINE THREONINE KINASE INHIBITOR ACTIVITY | 7 | 12 | 1.346e-15 | 3.126e-13 |
| 5 | ENZYME BINDING | 28 | 1737 | 1.766e-14 | 3.281e-12 |
| 6 | KINASE REGULATOR ACTIVITY | 12 | 186 | 3.429e-13 | 5.31e-11 |
| 7 | TRANSCRIPTION FACTOR BINDING | 16 | 524 | 2.687e-12 | 3.566e-10 |
| 8 | KINASE INHIBITOR ACTIVITY | 9 | 89 | 6.487e-12 | 7.533e-10 |
| 9 | PROTEIN KINASE ACTIVITY | 16 | 640 | 5.344e-11 | 5.516e-09 |
| 10 | PROTEIN COMPLEX BINDING | 18 | 935 | 1.894e-10 | 1.759e-08 |
| 11 | KINASE ACTIVITY | 17 | 842 | 3.284e-10 | 2.774e-08 |
| 12 | MACROMOLECULAR COMPLEX BINDING | 20 | 1399 | 2.679e-09 | 2.074e-07 |
| 13 | TRANSFERASE ACTIVITY TRANSFERRING PHOSPHORUS CONTAINING GROUPS | 17 | 992 | 3.952e-09 | 2.824e-07 |
| 14 | PROTEIN SERINE THREONINE KINASE ACTIVITY | 12 | 445 | 8.25e-09 | 5.475e-07 |
| 15 | RNA POLYMERASE II TRANSCRIPTION FACTOR BINDING | 7 | 104 | 2.904e-08 | 1.798e-06 |
| 16 | STEROID HORMONE RECEPTOR BINDING | 6 | 81 | 1.7e-07 | 9.869e-06 |
| 17 | ENZYME REGULATOR ACTIVITY | 14 | 959 | 8.445e-07 | 4.615e-05 |
| 18 | TRANSCRIPTION FACTOR ACTIVITY PROTEIN BINDING | 11 | 588 | 1.424e-06 | 7.347e-05 |
| 19 | ENZYME INHIBITOR ACTIVITY | 9 | 378 | 2.039e-06 | 9.018e-05 |
| 20 | NF KAPPAB BINDING | 4 | 30 | 2.022e-06 | 9.018e-05 |
| 21 | P53 BINDING | 5 | 67 | 1.865e-06 | 9.018e-05 |
| 22 | CYCLIN DEPENDENT PROTEIN KINASE ACTIVITY | 4 | 34 | 3.391e-06 | 0.0001432 |
| 23 | RNA POLYMERASE II ACTIVATING TRANSCRIPTION FACTOR BINDING | 4 | 36 | 4.288e-06 | 0.0001732 |
| 24 | ANDROGEN RECEPTOR BINDING | 4 | 39 | 5.946e-06 | 0.0002302 |
| 25 | CORE PROMOTER BINDING | 6 | 152 | 6.866e-06 | 0.0002551 |
| 26 | MOLECULAR FUNCTION REGULATOR | 15 | 1353 | 9.624e-06 | 0.0003439 |
| 27 | HORMONE RECEPTOR BINDING | 6 | 168 | 1.217e-05 | 0.0004038 |
| 28 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR BINDING | 3 | 15 | 1.197e-05 | 0.0004038 |
| 29 | CYCLIN BINDING | 3 | 19 | 2.526e-05 | 0.0008093 |
| 30 | ACTIVATING TRANSCRIPTION FACTOR BINDING | 4 | 57 | 2.741e-05 | 0.0008488 |
| 31 | NUCLEIC ACID BINDING TRANSCRIPTION FACTOR ACTIVITY | 13 | 1199 | 5.354e-05 | 0.001604 |
| 32 | SMAD BINDING | 4 | 72 | 6.899e-05 | 0.002003 |
| 33 | BHLH TRANSCRIPTION FACTOR BINDING | 3 | 28 | 8.376e-05 | 0.002358 |
| 34 | RNA POLYMERASE II TRANSCRIPTION FACTOR ACTIVITY SEQUENCE SPECIFIC DNA BINDING | 9 | 629 | 0.0001144 | 0.003038 |
| 35 | RECEPTOR BINDING | 14 | 1476 | 0.0001117 | 0.003038 |
| 36 | ADENYL NUCLEOTIDE BINDING | 14 | 1514 | 0.0001463 | 0.003774 |
| 37 | UBIQUITIN LIKE PROTEIN LIGASE BINDING | 6 | 264 | 0.0001511 | 0.003793 |
| 38 | REGULATORY REGION NUCLEIC ACID BINDING | 10 | 818 | 0.0001685 | 0.004119 |
| 39 | TRANSCRIPTION COACTIVATOR ACTIVITY | 6 | 296 | 0.0002801 | 0.006672 |
| 40 | CHROMATIN BINDING | 7 | 435 | 0.0003477 | 0.008075 |
| Num | GO | Overlap | Size | P Value | Adj. P Value |
|---|---|---|---|---|---|
| 1 | CYCLIN DEPENDENT PROTEIN KINASE HOLOENZYME COMPLEX | 8 | 31 | 3.47e-14 | 2.027e-11 |
| 2 | TRANSCRIPTION FACTOR COMPLEX | 14 | 298 | 2.355e-13 | 6.875e-11 |
| 3 | CHROMOSOME | 19 | 880 | 7.173e-12 | 1.05e-09 |
| 4 | PROTEIN KINASE COMPLEX | 9 | 90 | 7.191e-12 | 1.05e-09 |
| 5 | TRANSFERASE COMPLEX | 15 | 703 | 2.091e-09 | 2.442e-07 |
| 6 | CHROMOSOMAL REGION | 11 | 330 | 4.189e-09 | 4.077e-07 |
| 7 | CHROMATIN | 12 | 441 | 7.461e-09 | 6.225e-07 |
| 8 | TRANSFERASE COMPLEX TRANSFERRING PHOSPHORUS CONTAINING GROUPS | 9 | 237 | 4.017e-08 | 2.933e-06 |
| 9 | NUCLEAR CHROMOSOME | 12 | 523 | 4.898e-08 | 3.178e-06 |
| 10 | CATALYTIC COMPLEX | 15 | 1038 | 3.593e-07 | 2.098e-05 |
| 11 | NUCLEOLUS | 13 | 848 | 1.298e-06 | 6.892e-05 |
| 12 | CHROMOSOME TELOMERIC REGION | 6 | 162 | 9.89e-06 | 0.0004813 |
| 13 | MICROTUBULE CYTOSKELETON | 13 | 1068 | 1.599e-05 | 0.0007182 |
| 14 | SPINDLE | 7 | 289 | 2.738e-05 | 0.001142 |
| 15 | NUCLEAR CHROMOSOME TELOMERIC REGION | 5 | 132 | 5.134e-05 | 0.001999 |
| 16 | CENTROSOME | 8 | 487 | 0.0001107 | 0.004041 |
| 17 | CHROMOSOME CENTROMERIC REGION | 5 | 174 | 0.0001888 | 0.006485 |
| 18 | NUCLEOPLASM PART | 9 | 708 | 0.000277 | 0.008987 |
Over-represented Pathway
| Num | Pathway | Pathview | Overlap | Size | P Value | Adj. P Value |
|---|---|---|---|---|---|---|
| 1 | hsa04110_Cell_cycle | 61 | 128 | 5.025e-142 | 9.045e-140 | |
| 2 | hsa04115_p53_signaling_pathway | 16 | 69 | 1.114e-26 | 1.002e-24 | |
| 3 | hsa04151_PI3K_AKT_signaling_pathway | 17 | 351 | 2.573e-16 | 1.544e-14 | |
| 4 | hsa04390_Hippo_signaling_pathway | 13 | 154 | 9.554e-16 | 4.299e-14 | |
| 5 | hsa04350_TGF.beta_signaling_pathway | 11 | 85 | 1.471e-15 | 5.295e-14 | |
| 6 | hsa04114_Oocyte_meiosis | 10 | 114 | 1.712e-12 | 5.135e-11 | |
| 7 | hsa04310_Wnt_signaling_pathway | 9 | 151 | 7.782e-10 | 2.001e-08 | |
| 8 | hsa04914_Progesterone.mediated_oocyte_maturation | 6 | 87 | 2.607e-07 | 5.867e-06 | |
| 9 | hsa04722_Neurotrophin_signaling_pathway | 6 | 127 | 2.429e-06 | 4.858e-05 | |
| 10 | hsa04012_ErbB_signaling_pathway | 5 | 87 | 6.811e-06 | 0.0001226 | |
| 11 | hsa04630_Jak.STAT_signaling_pathway | 6 | 155 | 7.681e-06 | 0.0001257 | |
| 12 | hsa04520_Adherens_junction | 4 | 73 | 7.283e-05 | 0.001092 | |
| 13 | hsa04010_MAPK_signaling_pathway | 6 | 268 | 0.0001639 | 0.00227 | |
| 14 | hsa04330_Notch_signaling_pathway | 3 | 47 | 0.0003978 | 0.005115 | |
| 15 | hsa04510_Focal_adhesion | 4 | 200 | 0.003246 | 0.03851 | |
| 16 | hsa04144_Endocytosis | 4 | 203 | 0.003423 | 0.03851 | |
| 17 | hsa04916_Melanogenesis | 3 | 101 | 0.003638 | 0.03852 | |
| 18 | hsa03030_DNA_replication | 2 | 36 | 0.005393 | 0.05393 | |
| 19 | hsa03420_Nucleotide_excision_repair | 2 | 45 | 0.008327 | 0.07888 | |
| 20 | hsa04120_Ubiquitin_mediated_proteolysis | 3 | 139 | 0.008813 | 0.07931 | |
| 21 | hsa04720_Long.term_potentiation | 2 | 70 | 0.01935 | 0.1658 | |
| 22 | hsa04360_Axon_guidance | 2 | 130 | 0.05984 | 0.4683 |
lncRNA-mediated sponge
| Num | lncRNA | miRNAs | miRNAs count | Gene | Sponge regulatory network | lncRNA log2FC | lncRNA pvalue | Gene log2FC | Gene pvalue | lncRNA-gene Pearson correlation |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | AC005682.5 | hsa-miR-106a-5p;hsa-miR-10a-3p;hsa-miR-130b-5p;hsa-miR-141-3p;hsa-miR-182-5p;hsa-miR-191-5p;hsa-miR-200a-3p;hsa-miR-20b-5p;hsa-miR-28-5p;hsa-miR-3065-3p;hsa-miR-3065-5p | 11 | CCND2 | Sponge network | -2.193 | 0.07184 | -2.811 | 0.0014 | 0.394 |
| 2 | RP11-244O19.1 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15b-5p;hsa-miR-182-5p;hsa-miR-183-5p;hsa-miR-191-5p;hsa-miR-200a-3p;hsa-miR-3065-3p;hsa-miR-3065-5p;hsa-miR-30d-3p;hsa-miR-93-5p | 12 | CCND2 | Sponge network | -1.318 | 0.0924 | -2.811 | 0.0014 | 0.383 |
| 3 | DIO3OS | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-130b-5p;hsa-miR-141-3p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-182-5p;hsa-miR-183-5p;hsa-miR-191-5p;hsa-miR-200a-3p;hsa-miR-20b-5p;hsa-miR-324-3p;hsa-miR-378a-3p | 13 | CCND2 | Sponge network | -4.295 | 0.00689 | -2.811 | 0.0014 | 0.374 |
| 4 | RP11-166D19.1 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-130b-5p;hsa-miR-141-3p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-182-5p;hsa-miR-183-5p;hsa-miR-191-5p;hsa-miR-200a-3p;hsa-miR-20b-5p;hsa-miR-224-3p;hsa-miR-324-3p;hsa-miR-33a-3p;hsa-miR-378a-3p;hsa-miR-429;hsa-miR-550a-5p;hsa-miR-96-5p | 18 | CCND2 | Sponge network | -4.209 | 2.0E-5 | -2.811 | 0.0014 | 0.339 |
| 5 | RP11-439M11.1 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-130b-5p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-182-5p;hsa-miR-183-5p;hsa-miR-191-5p;hsa-miR-20b-5p;hsa-miR-324-3p | 10 | CCND2 | Sponge network | -2.662 | 0.21003 | -2.811 | 0.0014 | 0.337 |
| 6 | MAGI2-AS3 |
hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-130b-5p;hsa-miR-141-3p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-182-5p;hsa-miR-183-5p;hsa-miR-191-5p;hsa-miR-200a-3p;hsa-miR-20b-5p;hsa-miR-224-3p;hsa-miR-3065-5p;hsa-miR-30d-3p;hsa-miR-33a-3p;hsa-miR-378a-3p;hsa-miR-429;hsa-miR-9-3p;hsa-miR-93-5p | 19 | CCND2 | Sponge network | -4.563 | 0 | -2.811 | 0.0014 | 0.315 |
| 7 | RP11-284N8.3 | hsa-miR-106b-5p;hsa-miR-130b-5p;hsa-miR-141-3p;hsa-miR-182-5p;hsa-miR-183-5p;hsa-miR-200a-3p;hsa-miR-3065-5p;hsa-miR-324-3p;hsa-miR-93-5p;hsa-miR-96-5p | 10 | CCND2 | Sponge network | -0.845 | 0.52848 | -2.811 | 0.0014 | 0.313 |
| 8 | GAS6-AS2 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-130b-5p;hsa-miR-141-3p;hsa-miR-15b-5p;hsa-miR-182-5p;hsa-miR-183-5p;hsa-miR-191-5p;hsa-miR-200a-3p;hsa-miR-20b-5p;hsa-miR-28-5p;hsa-miR-3065-5p;hsa-miR-324-3p;hsa-miR-429 | 14 | CCND2 | Sponge network | -1.941 | 0.0681 | -2.811 | 0.0014 | 0.301 |
| 9 | RP11-389C8.2 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-130b-5p;hsa-miR-141-3p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-182-5p;hsa-miR-183-5p;hsa-miR-191-5p;hsa-miR-200a-3p;hsa-miR-224-3p;hsa-miR-3065-3p;hsa-miR-3065-5p;hsa-miR-33a-3p;hsa-miR-429;hsa-miR-550a-5p;hsa-miR-93-5p | 17 | CCND2 | Sponge network | -3.089 | 2.0E-5 | -2.811 | 0.0014 | 0.293 |
| 10 | RP11-554A11.4 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-130b-5p;hsa-miR-15b-5p;hsa-miR-182-5p;hsa-miR-183-5p;hsa-miR-191-5p;hsa-miR-20b-5p;hsa-miR-324-3p;hsa-miR-33a-3p | 10 | CCND2 | Sponge network | -5.361 | 2.0E-5 | -2.811 | 0.0014 | 0.29 |
| 11 | MIR143HG |
hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-130b-5p;hsa-miR-141-3p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-182-5p;hsa-miR-183-5p;hsa-miR-191-5p;hsa-miR-200a-3p;hsa-miR-20b-5p;hsa-miR-224-3p;hsa-miR-3065-3p;hsa-miR-3065-5p;hsa-miR-30d-3p;hsa-miR-324-3p;hsa-miR-33a-3p;hsa-miR-378a-3p;hsa-miR-429;hsa-miR-550a-5p;hsa-miR-93-5p | 21 | CCND2 | Sponge network | -6.51 | 0 | -2.811 | 0.0014 | 0.285 |
| 12 | SOCS2-AS1 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-130b-5p;hsa-miR-141-3p;hsa-miR-15b-5p;hsa-miR-182-5p;hsa-miR-183-5p;hsa-miR-200a-3p;hsa-miR-20b-5p;hsa-miR-324-3p;hsa-miR-33a-3p;hsa-miR-93-5p | 12 | CCND2 | Sponge network | -4.167 | 1.0E-5 | -2.811 | 0.0014 | 0.258 |
| 13 | RP11-597D13.9 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-130b-5p;hsa-miR-141-3p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-182-5p;hsa-miR-183-5p;hsa-miR-200a-3p;hsa-miR-20b-5p;hsa-miR-30d-3p;hsa-miR-429;hsa-miR-93-5p;hsa-miR-96-5p | 14 | CCND2 | Sponge network | -2.494 | 0.07597 | -2.811 | 0.0014 | 0.252 |
| 14 | DNM3OS | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-130b-5p;hsa-miR-141-3p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-182-5p;hsa-miR-183-5p;hsa-miR-191-5p;hsa-miR-200a-3p;hsa-miR-3065-3p;hsa-miR-3065-5p;hsa-miR-30d-3p;hsa-miR-33a-3p;hsa-miR-378a-3p;hsa-miR-429;hsa-miR-550a-5p;hsa-miR-93-5p;hsa-miR-96-5p | 19 | CCND2 | Sponge network | -3.933 | 0.00059 | -2.811 | 0.0014 | 0.25 |